±`¨£¥Ö½§¯f ¦Cªí

²§¦ì©Ê¥Ö½§ª¢¤â¥Uatopic dermatitis(11p)
  §@ªÌ¡G½²§eªÚ
¾\Äý¡G34845   
½²§eªÚÂå®v www.DrSkin.com.tw

 

²§¦ì©Ê¥Ö½§ª¢¤â¥U¡£¥D­n¨Ì¾Ú¬ü°ê°ê½Ã°|©ÒÄÝ°ê¥ßÃö¸`ª¢¡B¦Ù¦×¡B°©Àf¤Î¥Ö½§¯f¨ó·|03-4272¡¤(ETFAD/EADV eczema task force 2009, JEADV 2010;24:317)

 

¤°»ò¬O²§¦ì©Ê¥Ö½§ª¢(²§¦ì©Ê¥Ö½§ª¢)
²§¦ì©Ê¥Ö½§ª¢¬O¤@ºØªø´Á¡BºC©Êªº¥Ö½§¯e¯f¡A²³æªº»¡´N¬O²§¦ì©ÊÅé½è¾É­Pªº¥Ö½§ª¢¡C²§¦ì©Ê¥Ö½§ª¢¤£·|¶Ç¬V¡A¤£·|¦]±µÄ²¦Ó¥Ñ§O¤H¨­¤W±o¨ì²§¦ì©Ê¥Ö½§ª¢¡C¡¨¥Ö½§ª¢¡¨´N¬O«ü¥Ö½§µoª¢¡A¤]¥s°µ¡¨·Ã¯l¡¨¡C¦Ó²§¦ì©Ê(atopic)¬O«ü¤@¸s¨ã¦³¿ò¶Ç¶É¦Vªº¹L±Ó©Ê¯e¯f¡A¥]¬A®ð³Ý¡Bªá¯»¼ö¤Î¹L±Ó©Ê»óª¢¡A¦h¼Æ±wªÌ¦å²M¤¤E«¬§K¬Ì²y³J¥Õ¤É°ª¡C¦b²§¦ì©Ê¥Ö½§ª¢±wªÌ¡A±`¥Ö½§«ÜÄo¡A·k§ì«á·|¤Þ°_¥Ö½§µo¬õ¡A¯B¸~¡BÀtµõ¡Bº¯¤ô¡A³Ì«á¤Þ°_µ²¯m¤Î²æ¥Ö¡C¦h¼Æ±wªÌ¡A¯f±¡®É¦n®ÉÃa¡A¦³®É·|§¹¥þ¦n±¼¡AÁ{§É¤WºÙ¦¹¬° ¡¨²¬Â¡¡¨¡B¡¨½wÂࡨ¡A³¡¤À¤p«Äªº²§¦ì©Ê¥Ö½§ª¢·|ÀH¦~¬ö¼Wªø¦Ó§ïµ½©Î§¹¥þ®ø¥¢¡A¦ý¦h¼Æªº¥Ö½§¤´¸û¬°°®Àê¥B®e©ö¨ü¨ë¿E¡A¦b¨ä¥L²§¦ì©Ê¥Ö½§ª¢¤p«Ä¡A²§¦ì©Ê¥Ö½§ª¢·|¤@ª½«ùÄò¨ì¦¨¤H´Á¡C
¥Ö½§ª¢»P·Ã¯l¥i¥H·í§@¦P¸qµü¡A¦Ó²§¦ì©Ê¥Ö½§ª¢¬O·Ã¯l¤¤ªº¤@ºØ¡A³Ì¦­¬O¦b1808¦~¥ÑRobert Willan©Ò´£¥XÄo¯l¯ë¥Ö½§¯fÄ·¡A1891¦~Brocq¤ÎJacquet©R¦W¬°¼½´²©Ê¯«¸g©Ê¥Ö½§ª¢(disseminated neuridermatitis)¡A¥H±j½Õ±¡ºüªº¼vÅT¡A1892¦~¥ÑBesnierµo²{¦¹¯e¯f·|¦ñÀHªá¯»¼ö¤Î®ð³Ý¡A1923¦~Cova­º¥ý´£¥Xatopy¦Wµü¡A¥H±j½Õ¦¹¯e¯f¤§¯S®í©Ê(atopy = without place¡AµLªkÂkÃþ)¡A1930¦~Sulzberger©w¦W¬°atopic dermatitis, ³Ìªñ¼Ú¬w¹L±Ó¤ÎÁ{§É§K¬Ì¾Ç·|¤S´£¥X²§¦ì©Ê·Ã¯l/¥Ö½§ª¢¼x­Ô¸s¤@µü(AEDS))¡A»{¬°²§¦ì©Ê¥Ö½§ª¢¨Ã«D³æ¤@¯e¯f¡C¤£¦P·Ã¯l¶¡¦³¬Û¦üªºÁ{§É¯S©Ê¡A±`¨£ªº·Ã¯lÃþ§O¦p¤U:
(1)¹L±Ó©Ê±µÄ²©Ê·Ã¯l(¥Ö½§ª¢);¦]¥Ö½§±µÄ²¯S®íª«½è¡A¤Þ°_§K¬Ì¨t²Î¬¡¤Æ¡A¤Þ°_µo¬õ¡BÄo¡Bº¯²G²{¶H¡A±`¨£ª«½è¦p¨¾»G¾¯¡B­»®Æ¡BÂì¡B¬V¾v¾¯¡C
(2)¦½疱¯l¡A¤SºÙ²§¦½©Ê·Ã¯l¡A«ü¤â¡B¨¬ªº«æ©Ê¤ôªw©Ê·Ã¯l¡A¦h¦³¨ë¡BÄoªº¯gª¬¡C
(3)¯«¸g©Ê¥Ö½§ª¢:¤@¯ë«üºC©Ê³æ¯Â©Ê­aÅ~¡A±`¦bÀY³¡¡A¤p»L¡A«eÁu¡AµÃ³¡¥X²{¡A±`¬O§½³¡Äo¡A¸g·k§ì«á²£¥Í§½³¡¼W«p²{¶H¡C
(4)¿ú¹ôª¬·Ã¯l:¦]§e²{¿ú¹ôª¬¶ê«¬¯f¨_¦Ó±o¦W¡A¥D­n¬O¦b¤âÁu¡B­I³¡¡BÁv³¡¡B¤â­I¡B¤UªÏ¡A¤@¯ë¬ÆÄo¡A°£µo¬õ¥~¡A¤]¥i¯à¦³¤p¤ôªw¡B²æ¥Ö¡Bµ²¯m²{¶H¡C
(5)¯×º|©Ê¥Ö½§ª¢:¥D­n¬O¦bÀY¥Ö¡BÁy³¡¡A²£¥Í¶À¦â¡Aªo¿°ª¬²æ¥Ö´³¶ô¡A¦³®É¤]·|«I¥Ç«e¯Ý¡B«á¤W­I³¡µ¥°Ï°ì¡C
(6)Æ{¿n©Ê·Ã¯l:¤UªÏ¦]´`Àô¤£¨}¤Þ°_ªº¥Ö½§µoª¢²{¶H¡C
 
²§¦ì©Ê¥Ö½§ª¢µo¥Í¤Î²±¦æ²v (Immunol Allergy Clin North Am 2010; 30(3); 269-80)
²§¦ì©Ê¥Ö½§ª¢¬O¤Q¤À±`¨£ªº¥Ö½§¯f¡A¨k¤k³£¦³¡AÁöµM²§¦ì©Ê¥Ö½§ª¢¦b¦U¦~ÄÖ¼h³£·|µo¥Í¡A¦ý¦h¼Æ±qÀ¦¨à©Î¤p«Ä®É¶}©lµo¯f¡C¤§«e²Î­p¡A65%ªº±wªÌ²Ä¤@­Ó¯gª¬¥X²{©ó1·³«e¡A90%ªº±wªÌ5·³«eµo¯f¡A¦¨¤H(30·³)¥H¤W¤~µo¯fªÌ¸û¤Ö¡A¥B±`¬O±µÄ²¨ë¿Eª«½è©Î¬OÃnÅS¦b¼é·ÃÀô¹Ò¤Uµo¯f¡C¦ý³Ìªñ¤]¦³²Î­pµo²{¦³¬ù1/3·|ªÌ¬O¦b5·³«á¤~µo¯f¡C²§¦ì©Ê¥Ö½§ª¢¬O¤@­Ó±`¨£ªºÂ¾·~©Ê¨a®`¡A¦í¦b«°¥«¤º¤Î°®ÀêÀô¹Ò¤U¦ü¥G¸û©ö²£¥Í¡C²§¦ì©Ê¥Ö½§ª¢ªº¹ê»Ú±wªÌ¼ÆÃø¥H½T©w¡A¦ý±À¦ô20%ªºÀ¦¨à¤Î¥®¨à¦³²§¦ì©Ê¥Ö½§ª¢ªº¯gª¬¡A¨ä¤¤¤j¬ù60%ªº±wªÌ¨ì¦¨¤H´Á¤´¦³³¡¤À¯gª¬¡C¦b¤u·~¤Æ°ê®a¡A¥Ø«e¤p«Ä10-20%¦³²§¦ì©Ê¥Ö½§ª¢¡A¥B²§¦ì©Ê¥Ö½§ª¢¦³µo¥Í²v¼W¥[²{¶H¡A¦p­^°ê¦b1964¡B1989¡B1994¡B1999¤§²±¦æ²v¤À§O¬°5%¡B12%¡B18%¡B21%¡A¦ý¼W¥[ÁͶժñ¦~¥H¦³Áͽw¡C¥xÆW°ê½Ã°|ªº¬ã¨s³ø§i¤]Åã¥Ü2001¦~»P2004-2005¦~¬Û¤ñ¡A12-15·³«C¤Ö¦~¤@¦~²±¦æ²v¼W¥[²v¹F43%¡C(CED 2007 April)¡A¦Ü©ó°·«O¸ê®Æ®w¤¤²±¦æ²v¬°6.7%(ADV 2010:90:589)¡A¦]¦¹µØ¤H¾ãÅé¦Ó¨¥µo¥Í²v¬O¸û°ªªº(DC 21:669)

²§¦ì©Ê¯e¯f¦h¼Æ±q7·³«á§ïµ½(JACI 2006;118:152-69)¡A¼w°ê©ó2857¦ì«C¤Ö¦~(9~11·³)¬ã¨s¡A²±¦æ²v¬°1.7%¡A¦³47.6%·|«ùÄò¾H¦¨¤H¡A¦MÀI¦]¤l¥]¬A°ªªÀ¸g¦a¦ì¡B¤k©Ê¡B®ð³Ý¡B¥Ö½§¬ï´ú¤ÏÀ³¶§©Ê¡B®aªø¦³²§¦ì©ÊÅé½è¤Î±q¨Æ°ª¦MÀI¤u§@¡C(JACI 2010;126:590-5)
 
²§¦ì©Ê¥Ö½§ª¢ªºªá¶O
¦b¬ü°ê¤@¶µ·sªñ¤ÀªR¡A¦b5¦Ê¸U65·³¥H¤U«OÀI¤H¤¤¡A¬ù2.5%¦³²§¦ì©Ê¥Ö½§ª¢¡C¨C¤H¨C¦~«OÀI¤ä¥X¬°580~1250¬ü¤¸¡A¬ù¦û¤F³o¨Ç±wªÌ1/4¥H¤WÂåÀø¤ä¥X¡Aµ²½×¬O¬ü°êªº«OÀI¤½¥q¨C¦~ªá¶O¶W¹L¤@¥ü¬ü¤¸¦b²§¦ì©Ê¥Ö½§ª¢±wªÌ¡C
 
²§¦ì©Ê¥Ö½§ª¢ªº¦¨¦](N Engl J Med. 2008 Apr 3;358(14):1483-94)
²§¦ì©Ê¥Ö½§ª¢ªº¦¨¦]¤£©ú¡A¦ý»P¿ò¶Ç©MÀô¹Ò¦]¯À³£¦³Ãö¡A¥Ø«e¦³¶W¹L40­Ó¦]¤l³Q»{¬°¦³Ãö¡C¦b¿ò¶Ç¤è­±¡A¦pªG¤÷¥À¤@¤è¦³¹L±ÓÅé½è¡A¦p²§¦ì©Ê¥Ö½§ª¢¡B®ð³Ý¡Bªá¯»¼ö¡A¨º»ò¤p«Ä¦³²§¦ì©Ê¥Ö½§ª¢ªº¥i¯à©Ê´N·|ª@°ª¡AÁöµM¤@¨Ç²§¦ì©Ê¥Ö½§ª¢¤p«Äªø¤j«á¥Ö½§¯gª¬·|§ïµ½¡A¦ý3/4ªº¤p«Äªø¤j«á·|²£¥Íªá¯»¼ö©Î®ð³Ý¡A·í¦³²§¦ì©Ê¥Ö½§ª¢¿ò¶ÇÅé½è¦s¦b®É¡AÀô¹Ò¦]¯ÀÀH®É¥i¯à·|»¤µo²§¦ì©Ê¥Ö½§ª¢ªº¯gª¬¥X²{¡C¤]¦³¬ã¨s«ü¥X¦b­L¨à©Î¬O­÷¨Å¦Ó±µÄ²¥ÀÅé¨Ï¥Îªº§Ü¥Í¯À·|¼W¥[¹L±Ó¯gª¬¡A¦Ó¥X¥Í«á¨Ï¥Î§Ü¥Í¯À¤Ï¦Ó·|´î¤Ö¹L±Ó¯gª¬(Clinical and Experimental Allergy,)¡C´¿³ø§i²§±`°ò¦]¬V¦âÅé¦ì¸m¥]¬A1q21, 3q21,5q31-33, 16q12, 17q11, 17q25¡A³¡¥÷°ò¦]»P°®Å~­«Å|¡C¦b¿ò¶Ç¦]¯À¤¤¡A§K¬Ì©Ê¤Î«D§K¬Ì©Ê¦]¯À³£«Ü­«­n¡C¨Ò¦p2012¦~ªº¤@¶µ¤j«¬°ò¦]¬ã¨sµo²{°£¤F¤wª¾filaggrin°ò¦]¥~¡A»Pªí¥Ö¼W¥Í¤Î¤À¤Æ¬ÛÃöªºOVOL1¤ÎACTL9¡AÁÙ¦³»PIL13ªí²{¬ÛÃöªºKIF3A, CARD11³£¦³Ãö¡C(Paternoster L, Standl M, Chen CM, et al. Nat Genet. 2012).
 thymic stromal lymphopoietin (TSLP)«h¬O¥t¤@­Ó¬ÛÃö°ò¦]¡A¤]»P¬O§_®e©ö¦³疱¯l©ÊÀã¯l¦³Ãö¡C
¥t¥~ªº¬ã¨sÅã¥Ü8·³«e·P¬V¹L¤ôµkªÌµo¥Í²§¦ì©Ê¥Ö½§ª¢¾÷·|¤U­°
 
²§¦ì©Ê¥Ö½§ª¢±wªÌªº§K¬Ì¥\¯à²§±`¡A¥]¬A¦³µLªk¾A·íªº¹ï§Ü²Óµß©M¯f¬r¡A¥H¤Î¿ï¾Ü©Êªº³¡¥÷¥~¦bª«½è²£¥Í¹L¦hªºTh2¤ÏÀ³¡A¤]´N¬O¹L±Ó¡C¬y¦½¤Þ°_ªº´c¤Æ«h¦­¬°¤Hª¾¡A³ÌªñMGL_1304 secreted by Malassezia globosa ³Qµo²{¬O¥i¯à¦]¯À¡C¤£¦P¦~ÄÖ¼hªº´c¤Æ¦]¯À¤£¦P¡A­¹ª«¥®¨à®É©úÅã¡A¦¨¤H¨¤¦â¤U­°¡A¥Ö®hªÞÌUµß«h¬O«C¬K´Á«á¤~©úÅã¡A¦Ó¯f¬r¤Î²Óµß«h¬O¨¤¦â©l²×­«­n¡A¦ý§l¤J©Ê§Ü­ì«h¬O¤p¦Ó¶}©l¥X²{(I Allergy Clin Immunol 2006;118:152)¡C²§¦ì©Ê¥Ö½§ª¢±wªÌ¯Ê¥F¤@¨Çºû«ù¤HÅé°·±d©Ò¥²»Ýªº²Ó­M¿E¯À(Interferon-gamma)¡A«o¤S²£¥Í¹L¦h¤Þ°_¹L±Ó¤ÏÀ³ªº²Ó­M¿E¯À(IL4, IL5, IL13, IL16, RANTES, MCP4, eotaxin)¡A70-80% IgE¤W¤É¡A¶Ý¨Ì¬õ²y¼W¥[¡C¥t¥~ªº¤@ºØ¬Ýªk«h¬OTh1©ÎT½Õ¸`²Ó­M(Treg)ªº¥\¯à¯Ê³´¡A¾É­PTh2¥\¯à¤W¤É¡C°Ñ»P²§¦ì©Ê¥Ö½§ª¢µoª¢ªº¤HÅé²Ó­M¥D­n¬OCD4¤ÎCD8ªºT²Ó­M¡A¥t¥~¨¤½è²Ó­M¡B¾ð¬ð²Ó­M(§Ü­ì§e²{²Ó­M§tIDEC)¡ANK ¤ÎNKT²Ó­M¤Î±ß´Á¥X²{ªº¶Ý¥ì¬õ²y¡B¥¨¶Ý²Ó­M³£¦³Ãö«Y¡A»P®ð³Ý¤Î¹L±Ó©Ê»óª¢¡BëC³Â¯l¬ÛÃöªºªÎ¤j²Ó­M¡A¤Ï¦Ó»P²§¦ì©Ê¥Ö½§ª¢µL©úÅãÃö³s¡CIgE¦b²§¦ì©Ê±wªÌ¥i¯à¬O³z¹L¨ë¿E§Ü­ì§e²{²Ó­M(Langerhans cell)¤WªºIgE¨üÅé¡A¦Ó«Dmast cell¡C

³o¨Ç§Ü­ì§e²{²Ó­MÀH«á¤ÀªcIL-25¡AIL-25«h¨ë¿ET²Ó­M¤À¤Æ¦¨Th2²Ó­M¡A¦P®ÉIL-25·|§í¨îfilaggrinªº¦X¦¨¡A¦]¦Ó¤Þ°_¥Ö½§°®Äoµoª¢¡C


 ¤§«e²§¦ì©Ê¥Ö½§ª¢³Qµø¬°­Ó¤H±¡ºü¦Ó¤Þµo¡A¦­¦b1891¦~´NºÙ¬°¯«¸g©Ê¥Ö½§ª¢¡A¥Ø«e¹ï»¤¥Í²§¦ì©Ê¥Ö½§ª¢ªº¨ä¥L¦]¯À³vº¥©ú¥Õ¡A±¡ºü¨Ã¤£·|¤Þ°_²§¦ì©Ê¥Ö½§ª¢¡B¦ý¥i¯à¨Ï²§¦ì©Ê¥Ö½§ª¢´c¤Æ¡C ¦Ü©ó¤Þ°_Äoªº¾÷Âà¡A·sµo²{ªºgastrin releasing peptide¤ÎIL-31³Qµo²{¥i¯à§êºt­«­n¨¤¦â(Buddenkotte 2010 Allergy. 2010 Jul;65(7):805-21.)¡A¦Óªì´Á¯fÅÜ«h¦³¾ÇªÌµo²{¬O¦½¸¢¤fªºª÷¶À¦â¸²µå²yµß¡A§Î¦¨¥Íª«Á¡½¤¡A³z¹L¬¡¤Æ Toll-like receptor 2¦Ó»¤µoproteinase-activated receptor 2¤Þ°_µoÄo¡A¤Î³z¹LMyD88¤Þ°_Àã¯l¡C
²§¦ì©Ê¥Ö½§ª¢±wªÌªº«D§K¬Ì¥\¯à²§±`¡A¥Hªí¥Ö»Ù¾À²§±`§e²{¡A¤ô¥÷¸g¥Ö»]µo¼W¥[¡A¥Ö½§«OÅ@¥\¯à¤U­°¦P®É§l¦¬¯à¤O¤]¼W±j¡Cªí¥Ö»Ù¾À²§±`³Q»{¬°¬O­ìµo©Ê¯fÅÜ¡A»P¯«¸gñQ®òceramide¡Bspingosine¦X¦¨´î¤Ö¦³Ãö¡A·sªñ¬ã¨s¤]µo²{ªí¥Ö¤À¤Æ¬ÛÃö°ò¦]²§±`ªº­«­n©Ê¡A¯S§O¬Oµ·»E¦X³J¥Õ¡]filaggrin)°ò¦]¬ðÅÜ¡A¨ä¥L°ò¦]ÁÙ¥]¬ASPRINK5¡AKLK7¡Cfilaggrin°ò¦]¬ðÅܰꤺ¤]¦³¶E©Ò´ú¸Õ20­Ó±`¨£¦ìÂI¡A¦¬¶O3600¡C³o¨Çªí¥Ö¯Ê³´¡A¨Ï±o·L¥Íª«®e©ö´F¥Í¤Î¨ë¿Eªí¥Ö¡A³z¹L¦pª÷¶À¦â¸²µå²yµß¤Î»Ã¥ÀµßMalassezia sympodialis¡A¸g¹Lªí­±¥ý¤Ñ§K¬Ì©Ê¨üÅé¡A¦pNOD1, NOD2, TLR-2,TLR9¡A¨Ïªí¥Ö¤Àªc¥XTSLP¡A¨ë¿E¾ð¬ð²Ó­MÅý ²Ä2«¬T²O¤Ú²Ó­M¬¡¤Æ¦Ó¤Þ°_²§¦ì©Ê·Ã¯l¡Cª÷¶À¦â¸²µå²yµß¤ÎMalassezia sympodialis¤]¥i³z¹L¶W¯Å§Ü­ì©Î¬OÀÀ¦ÛÅé§Ü­ìªº¤è¦¡(Malassezia sympodialisªº§Ü­ìMala s 11»P¤HÅé»Ã¯ÀhMnSOD¬Û¦ü)¡A¤Þ°_«á¤Ñ§K¬Ì¨t²Î²§±`¡C¯S®íªº¬O¤£¦Pªºªí­±¨üÅé¤Þ°_¤£¦P¤U´å¤ÏÀ³¡A¦pTLR9ªº¨ë¿E¤Þ°_ªº¤ÏÀ³»PIgEµLÃö¡C
²§¦ì©Ê¥Ö½§ª¢ªº¥Ö½§¯S¼x
¨C­Ó¤Hªº²§¦ì©Ê¥Ö½§ª¢¥Ö½§ªí²{³¡¤À¥i¯à¦³¨Ç¤£¦P¡A¨ä¤¤³Ì±`¨£ªº¬O¥Ö½§°®¡BÄo¤Î¬õ¯l¡A¤×¨ä¦b¤â¨yÅs¦±³B¡A¸}çAºÛ¡B¤â¡B¨¬¤ÎÁy¤W¡AÄo¬O²§¦ì©Ê¥Ö½§ª¢«Ü­«­nªº¯gª¬¡AÄo·|¤Þµo·k§ì¤Î¼¯À¿¡A¤Þ°_µoª¢¡A¨Ï±oÄo§ó¬°ÄY­«¡AÄo·P¦bºÎ¯v¤¤±`§ó¬°©úÅã¡A¥BµLªk¥H·N§Ó¤O§J¨î¡C
²§¦ì©Ê¥Ö½§ª¢ªº¥Ö½§ªí²{¡A·|¨ü¨ì·kÄoµ{«×¤ÎÄ~µo©Ê·P¬Vªº¼vÅT¡C²§¦ì©Ê¥Ö½§ª¢ªº¥Ö½§ªí²{¡A¥Ñ¬õ¸~²æ¥Ö¡A¨ì¥Ö­²ª¬¼W­ì¡A©Î¬O¬õ¦â¥C¯l¡A¤p¤ôªw¨ì¯m¥Ö¡B·P¬V³£¦³¥i¯à¡C¤£¹L³o¨Ç¯gª¬¤]¥i¯à¦b¨ä¥L·Ã¯l±wªÌ¤W¥X²{¡A¨Ã«D¶È¨£©ó²§¦ì©Ê¥Ö½§ª¢±wªÌ¡C
²§¦ì©Ê¥Ö½§ª¢¤]¥i¯à«I¥Ç²´³ò¡A¥]¬A²´¥Ö¡B¬Ü¤ò¤Î·û¤ò¡A·k§ì·|¨Ï±o¥Ö½§¬õ¸~¡C¦³¨Ç±wªÌ·|¦b²´·ú¤U¤è²£¥ÍÃB¥~½K§é¡AºÙ¬°DENNIE¡XMORGAN½K§é¡A¥t¥~·k§ì¤Î¼¯À¿¤]·|¤Þ°_³¡¤À¬Ü¤ò¤Î·û¤ò±¼¸¨¡C
¨ä¥L²§¦ì©Ê¥Ö½§ª¢ªº¥Ö½§ªí²{ÁÙ¥]¬A¦³®Bª¢¡B¤â´x¯¾¸ô¹L¦h¡B¶Â²´°é¡B¤òÅn¨¤¤Æ¡BëC³Â¯lµ¥¡A²§¦ì©Ê¥Ö½§ª¢±wªÌªº¥Ö½§ÁÙ¦³¨ä¥Lªº²§±`¡A¨ä¤¤³Ì¥~¼hªº¨¤½è¼h¡A­ì¥»¬O­n¨¾¤î¥Ö½§°®Àê¤Îªý¹j¥~¬É¨ë¿Eª«¤Î¯fµß¶i¤J¤HÅé¡A¦ý²§¦ì©Ê¥Ö½§ª¢ªº¨¤½è¼h¦b³o¤è­±«h¬O¦³¥\¯à¤W¯Ê·l¡A¦]¦¹¤Þ°_°®Àê¡B«OÅ@¤O¤]¤U­°¡A¦A¥[¤W­ì¨Ó´N¦s¦bªº§K¬Ì²§±`¡A¦]¦¹§ó®e©ö³Q²Óµß¡B¯f¬r©Ò·P¬V¡C·íµM¡A²§¦ì©Ê¥Ö½§ª¢±wªÌ¤]¦³¦nªº¨Æ¡A´N¬O´c©Ê¶Â¦â¯À½F¤Î°ò©³²Ó­M½F¸û¤Ö( 2017 Dec;31(12):2083-2087)
 
²§¦ì©Ê¥Ö½§ª¢ªº¯fµ{µo®i(J Allergy Clin Immunol. 2006 ;118:152-69)
¶Ç²Î¤W§â²§¦ì©Ê¥Ö½§ª¢ªºµo®i¤À¬°¤T´Á¡A¦bÀ¦¨à´Á¡A²§¦ì©Ê¥Ö½§ª¢¦h¦b6~12¶g«e§e²{ªì´Á¯gª¬¡A­è¶}©l¬O¦bÀY¥Ö¡B­±ÀU¡BÃBÀY¡B¦Õ¦·¡B²ä¤l¤Î¤U¤Ú¥X²{´³¶ôª¬¬õ¯l¡A¤§«á³vº¥´c¤Æ¡A²æ¥Ö¤D¦Üº¯²G¬y´ö¡A¦A¤Þ°_²Óµß·P¬V¡C·íÀ¦¨à¶}©lª¦¦æ«á¡A¦b±µÄ²¦a­±³B¡A¦p¥|ªÏ¥~°¼¤Î¼¯À¿³B¤]³Q¼vÅT¡A¥Ñ©óµoª¢¤Þ°_¤£¾A¡AÀ¦¨à¥i¯à·|ļ°Ê¡C¤§«á¨ì¤F1·³¥b(2¡B3·³)®É¤S³vº¥§ïµ½¡A¦h¼Æ¦b7·³«e§ïµ½¡A¦ý³o¨Ç¤p«Ä¤é«áªø¤j®É¡A¤´µM¥i¯à·|¦³¤é«á¨ä¥L¥Ö½§°ÝÃD¡A¯S§O¬O¥Ö½§°®Àê©Î¤â³¡·Ã¯l¡C
¨ì¤F¤p¨à¶¥¬q¡A·Ã¯l¥D­n¦b¥|ªÏÅs¦±½K§é³B¡B²ä¤l¡B¤f³ò¡B¤Î¤âµÃ¡B¨¬½ï¡B¤â³¡¥X²{¡A­è¶}©l±`¨£¬õ¯l¡B¤§«á³vº¥Åܵw¡A·k§ì«á²æ¥Ö¡C¤f³ò¦]°®Àê¡B±`¤Þ°_¥Î¤f¤ô¥h»Q¡A¤f¤ôªº¨ë¿E»¤µo¤F¼F®`ªºµoª¢¤ÏÀ³¡A¬Æ¦ÜÀtµõ¯kµh¡C¤@¨Ç¤p«Äªº²§¦ì©Ê¥Ö½§ª¢¯gª¬·|¬ðµM®ø¥¢¤@¬q¤£µuªº®É¶¡¡A¨ì¤F«C¬K´Á¤~¤S¥X²{¡C¦¹®É»¤µo¦]¯À¥i¯à¥]¬A²üº¸»X§ïÅÜ¡BÀ£¤O¡A¤Î¨Ï¥Î¤£·í¨ë¿E©Êªº²M¼ä¡B«O¾i²£«~¡C
ÁöµM¦h¼Æ²§¦ì©Ê¥Ö½§ª¢±wªÌ±q¤p´N¥X²{¦³¯gª¬¡A¦ý²§¦ì©Ê¥Ö½§ª¢¤]¦³¥i¯à¨ì¤F¦¨¤H¤~¥X²{¡A¦¨¤Hªº²§¦ì©Ê¥Ö½§ª¢¥i¯à¬O§½³¡¥X²{¡A¤]¥i¥H¬O¥þ¨­¥X²{¯gª¬¡A³\¦h¬OIgE¼Æ½è¥¿±`¡A³¡¥÷¥i°»´ú¥Xanti-protease§ÜÅé¡AÄÝ©ó¦ÛÅé§K¬Ì©Ê¯e¯f¡CÁ|¨Ò¦Ó¨¥¡A¦¨¤H²§¦ì©Ê¥Ö½§ª¢¥i¥H¥u¦³¤â¡B¨¬·Ã¯l¡A©Î¬OÁy³¡¡B²ä¤l·Ã¯l(²§¦ì©Ê¬õÁy¯g)¡A©Î¬O¥þ¨­µo¬õ²æ¥Ö(¬õ¥Ö¯g)¡AÄY­«®É·|¼vÅTºÎ¯v¡A¨D¾Ç¤Î¤u§@¡A¶Ç²ÎªºªvÀø¬O¥HÃþ©T¾J¥~¥Î¡A¦ýªø´Á¥B¤£·í¨Ï¥ÎÃþ©T¾J¡A·|¤Þ°_³\¦hªº°Æ§@¥Î¡A¥t¥~²§¦ì©Ê¥Ö½§ª¢¦]¥Ö½§©è§Ü¡B«OÅ@¥\¯à­°§C¡A·í±µÄ²²M¼ä¾¯¡B¤ò®Æ¡B¦çªA¼¯À¿©Î¨ä¥L¨ë¿Eª«®É¡A¸û©ö¤Þ°_¥Ö½§¬õ¸~µoª¢¡A¦pªG¬O±q¨Æ»Ý­n®É±`¬~¤â©Î±µÄ²¤Æ¾Çª«½èªº¤u§@¡A§ó®e©ö²£¥Í¡C¦]¾·~¤Wªº»Ý¨D¡A³o¨Ç±wªÌ¯S§O¤£©öªvÀø¡C¥t¥~·Ã¯l¤]±`¦b¨ÅÀY¥X²{¡C°£¤F¥Ö½§¯gª¬¥~¡A²§¦ì©Ê¥Ö½§ª¢±wªÌ¤]®e©ö¦³¥Õ¤º»Ù¥X²{¡A¦]¦¹¤]»Ý­n©w´Á²´¬ìÀˬd¡C
 
²§¦ì©Ê¥Ö½§ª¢ªº¶EÂ_
¨C¦ì²§¦ì©Ê¥Ö½§ª¢±wªÌ³£¥i¯à¦³¦Û¤v¯S®íªº¥Ö½§¯gª¬²Õ¦X¡A¥B¦]®É¶¡¤£¦P¡AÄY­«©Ê¤]¤£¤@¼Ë¡AÂå®v«h·|¨Ì¾Ú­Ó¤H¸gÅç¤Î³o¨Ç¯gª¬²Õ¦X¡A¦Ó¶EÂ_²§¦ì©Ê¥Ö½§ª¢¡A¦³®É¦]¯gª¬¤£¬Æ©ú½T¡A©Ò¥H¥i¯à»Ý­nÆ[¹î¤@¬q®É¶¡¤~½T©w¶EÂ_¡C¦]²§¦ì©Ê¥Ö½§ª¢±`¦³®a±Ú¹L±Ó¥v¡A¦]¦¹®a¤¤¨ä¥L¦¨­û¡A©Î¥»¨­¬O§_¦³·Ã¯l¡Bªá¯»¼ö¡B®ð³Ý¡B¹L±Ó©Ê»óª¢µ¥¡A¦b¶EÂ_¤W³£«Ü¦³À°§U¡C¥t¥~­Ó¤H±µÄ²¥~¨Ó¨ë¿Eª«¡BºÎ¯v»Ùê¡B¤Î¬O§_¦³¯S©w­¹ª«·|¨Ï¥Ö½§¯gª¬´c¤Æ¡B¤§«e¥Ö½§ªvÀø±¡§Î¡B¨Ï¥Î¦óºØÃĪ«¡A³£¹ï¯e¯fªº¤F¸Ñ¦³À°§U¡C²§¦ì©Ê¥Ö½§ª¢ªºªí²{¨ÃµL¤@©wªº¤è¦¡¡A¦ý¦b°ê»Ú¤W¡A¬°¨D¤è«K·¾³q¡A¦b1980¦~Hanifin JM¤ÎRajka Gµ¥¾ÇªÌ´£¥X³q¥Îªº¶EÂ_­n¨D¡A¦b4¶µ¥D­n¯gª¬¤Î23¶µ¦¸­n¯gª¬¤¤¡A¦Ü¤Ö­n¦³¤T¶µ¥D­n¯gª¬¤Î¤T¶µ¦¸­n¯gª¬¡A¤~½T©w¬O²§¦ì©Ê¥Ö½§ª¢¡C1996¦~­^°ê¾ÇªÌWilliams HC´£¥X­×¥¿«áªº¶EÂ_¼Ð·Ç(Br J Dermatol. 2001145:428-33 & Br J Dermatol. 2005 ;152(4):735-41)¡A2005¦~¼w°ê¾ÇªÌRing J¤]´£¥X¦Û¤vªº«Øij¡C
¥Ø«e¨ÃµL³æ¶µ¶EÂ_¬O¥i¥H½T©w²§¦ì©Ê¥Ö½§ª¢¶EÂ_ªº¡A¦ý¦³¨ÇÀˬd¬O¥i¥HÀ°§UÂå®v¤F¸Ñ²§¦ì©Ê¥Ö½§ª¢ªº¹L±Ó±¡ªp¡A¦p¥Ö½§°w¨ë¤ÏÀ³(prick test)¬O§â¤Ö¶q¹L±Ó­ì¤ã¤J¥Ö½§¡A¦pªG§e²{³±©Ê¤ÏÀ³¡A¥i¥HÀ°§U±Æ°£¥Ö½§¹L±Ó­ì¡A¦ý¦pªG¬O¶§©Ê¤ÏÀ³¡A«h¤£¨£±o¬O¶§©Ê¤ÏÀ³ªºª«½è¡A³£¯u¥¿·|³y¦¨¦¹¤@±wªÌªº¥Ö½§¯gª¬¡C¥Î©â¦å¤è¦¡ÀË´ú¹L±Ó­ì¤]¬O¤@¼Ë¦³ÆF±Ó«×¤@¯ë¨¬°÷¡A¦ý¯S²§©Ê¡A¤]´N¬OÁ{§É¬ÛÃö©Ê¤£¨¬¤§±¡§Î¡A³o¬O¦]¬°¦å²G¤¤¦s¦bªº§ÜÅé¡A¤£¤@©w¦b¥Ö½§¤¤·|¾É­P¯gª¬¡A·íµM¦pªG¦å¤¤¯S©w§ÜÅé¼Æ­È«Ü°ª®É¡AÁ{§É¬ÛÃö©Ê¥i¯à¸û¬°©úÅã¡A¦ý¬O§_¯u¥¿¬ÛÃö¡AÁÙ¬O­n¾a±wªÌ¦Û¤vª`·N¡A§@¥Í¬¡¤é°OÆ[¹î¬O§_¦b±µÄ²©ÎªA¥Î³o¨Çª«½è«á¡A¥Ö½§¬O§_¯u¥¿´c¤Æ¡C°ê¥~¬ã¨sªñ30-40%¤¤­««×±wªÌ¦Ûı¦³­¹ª«¤Þ°_¥Ö½§´c¤Æ²{¶H¡A¤×¨ä¥®¨à¡A¦Ü©ó¹ÐÂکΰʪ«¤ò¡BÅðµßµ¥§l¤J©Ê¹L±Ó­ì¡A¦b¦³©I§l¹D¹L±ÓªÌ¤]¥i¯à»¤µo¥Ö½§¤ÏÀ³¡C¦bªù¶EÀˬd¤¤¡A¯S²§©Ê¸û°ªªº¬O²§¦ì©Ê¶K½§´ú¸Õ(APT)¡A¦b¤@¶µ¬ã¨s¤¤¥H314¦ì±wªÌ¡A¹ï¹ÐÂÚ¡B¿ß¤ò¡Bªá¯»¡BÂû³J¡Bªàµæ¡B¤p³Á¯»¦P®É¶i¦æ°w¨ë¤ÏÀ³¡B©â¦å´ú¯S©wIgE¤Î²§¦ì©Ê¶K½§´ú¸Õ¡Aµo²{¤TºØ´ú¸Õ¹ïªá¯»¤ÎªA¥ÎÂû³J¡A¤Þ°_ªº·Ã¯l´c¤Æ³£¨ã¦³Á{§É¬ÛÃö©Ê¡A¦ý¥H²§¦ì©Ê¶K½§´ú¸Õ¯S²§©Ê³Ì°ª¡A¦³60-90%¡A¦ý¬O°w¨ë¤ÏÀ³¡B©â¦å´ú¯S©wIgEÆF±Ó«×¸û°ª¡C²§¦ì©Ê¶K½§´ú¸Õ³Ì¤j»ù­È¬O¥Î©ó°»´úªÅ®ð¶Ç¼½©Ê¹L±Ó­ì¡A¦pªG±wªÌ¦b¥~ÅS³¡¦ì¦³Àã¯lªí²{®É¨Ï¥Î¡CªA¥Î¯S©w­¹ª«¡A©Î¬O¨è·N±Æ°£¯S©w­¹ª«¡A³£¥i§@¬°½T©w­¹ª«»P²§¦ì©Ê¥Ö½§ª¢¯gª¬¬ÛÃö©Ê¤§°Ñ¦Ò¡A¦ý³Ì¦n¦bÂå®v«ü¥Ü¤ÎºÊ·þ¤U¶i¦æ¡A¦ý§Y¨Ï¦p¦¹¡A¦]¬°²§¦ì©Ê¥Ö½§ª¢ªºÄY­««×·|¨ü¨ì³\¦h¦]¯Àªº¼vÅT¡A©Ò¥H³o¨Ç¹L±Ó­ì»P²§¦ì©Ê¥Ö½§ª¢ªºÃö³s©Ê¦³®É¹ê¦b¤£©ö½T©w¡C
 
¤Þ°_²§¦ì©Ê¥Ö½§ª¢´c¤Æªº­ì¦]
³\¦h¦]¯À¦p¨ë¿E¡B±¡ºüÀ£¤O¡B¤Ñ®ð¡B¶W¯Å§Ü­ì¡B·P¬V¡B§l¤J©Ê¹L±Ó­ì¡B­¹ª«¹L±Ó­ì¡B¶Pº¸»X³£¥i¯à¨Ï²§¦ì©Ê¥Ö½§ª¢ªº¯gª¬´c¤Æ¡A§K¬Ì¤O§ó¥[¥¢½Õ¡A¥Ö½§·kÄo¥[¼@¡A¨Ï±o¥Ö½§¶Ë®`¥[²`¡A³o¨Ç¦]¯À¥i²Ê¤À¬°¨ë¿E©Ê¤Î¹L±Ó©Êµ¥¤G¤jÃþ¡C¥Ö½§¨ë¿Eª«¡A·í¿@«×°ª©Î±µÄ²¥Ö½§®É¶¡°÷ªø®É¡A·|¨Ï±o¥Ö½§µo¬õ¡B·kÄo¡A¬Æ¦Ü¨`¶Ë¡C¤£¦P¨ë¿Eª«½è¦b¤£¦P¤H¨­¤W¨ë¿Eªºµ{«×¤]¤£¦P¡A¸g¥ÑÆ[¹î¾Ç²ß¡A±wªÌ¤Î¨ä®a¤H¡A·|³vº¥§ä¥X¤Þ°_°ÝÃDªº¨ë¿Eª«¡AÁ|¨Ò¦Ó¨¥¡AÀWÁcªº¥Ö½§¼é·Ã¤Î°®Àê·|¼vÅT¥Ö½§ªº«OÅ@»Ù¾À¥\¯à¡C¦¹¥~¡A¤ò®Æ©Î¦X¦¨ÅÖºû©Ê¤Î²ÊÁW©Î¤£¦X¨­ªº¦çª«¡A³£¥i¯à¨ë¶Ë©Î¼¯À¿¥Ö½§¡A¤Þ°_µoª¢¡A¾É­PÄo¤Î·k§ìªº´c©Ê´`Àô¡CªÎ¨m¤Î²M¼ä¾¯¡A¤]¥i¯à·|¨Ï¥Ö½§°®Àß¡A¦Ó¨ÏÄo·P¼W¥[¡C¤@¨Ç­»®Æ¤Î¤ÆùÛ«~¦P¼Ë¥i¯à¨ë¿E¥Ö½§¡A±µÄ²·»¾¯¡B¯»¹Ð¤Î¬â¤l¤]¥i¯à¨Ïª¬ªp´c¤Æ¡A©â·Ï«h¥i¯à¨ë¿E²´¥Ö¡A¦]¬°³o¨Ç¨ë¿Eªº¤ÏÀ³·|¦]¤H¦Ó²§¡A¨C­Ó±wªÌ³Ì¦n¯à¦Û¤v§ä¥X¨ä´c¤Æ¦]¯À¡C¥t¥~¤]¦³¾ÇªÌµo²{¤@¨Ç¹L±Óª«½è¥i¯à¥Ñ¦½²G±Æ¥X¡A¦]°_µoÄo²{¶H¡C
¦Ü©ó¹L±Óª«½è«h¬O«ü­¹ª«¡B´Óª«¡B°Êª«©ÎªÅ®ð¤¤¡A¦]¨Ï§K¬Ì¤ÏÀ³¹L«×¬¡¤Æ¡A¦Ó¤Þ°_µoª¢ªºª«½è¡A³oºØµoª¢¤ÏÀ³¡A§Y¨Ï¥u¬O¤Ö¶q¡Bµu´Á±µÄ²³o¨Çª«½è¡A³£¥i¯à²£¥Í¡CÁöµM¥Ø«e¤wª¾ªÅ®ð¤¤§t¹L±Ó­ì¡A¦p¹ÐÂÚ¡Bªá¯»¡BÅðµß¤Î°Êª«¤ò¾v¡A¥i¯à·|¨Ï¬Y¨Ç¤H²§¦ì©Ê¥Ö½§ª¢´c¤Æ¡A¦ý¨s³º¬O¦]§l¤J³o¨Ç¹L±Ó­ì¡AÁÙ¬O¸g¥Ñ¥Ö½§¬ï³z¡A¥Ø«e©|µL©w½×¡C·í²§¦ì©Ê¥Ö½§ª¢±wªÌ±µÄ²¤W­z¨ë¿Eª«©Î¹L±Ó­ì®É¡A¥Ö½§µoª¢ª«¥Í¦¨¼W¥[¡A²Ó­M©ñ¥X¤Þ°_µo¬õ¡BµoÄoªº¤Æ¾Çª«½è¡A¦Ó·k§ì«h¨Ï¯gª¬¶i¤@¨B´c¤Æ¡C¿ß¤ò¤Îª¯¤ò³£¥i¯à·|¤Þ°_²§¦ì©Ê·Ã¯l´c¤Æ¡A¿ß¤ò§Ü­ìªº¦s¦b»P®a¤¤¬O§_¾i¿ß¦³Ãö¡A¦ýª¯¤ò«hµLÃö¡C®Ú¾Ú¾ÇªÌSchaferªº¬ã¨s¡A®a¤¤¾i¿ß²§¦ì©Ê·Ã¯l®e©ö´c¤Æ¡A¦ý¾iª¯«h¤£·|´c¤Æ¡A»{­P¦³«OÅ@®ÄªG¡C¦Ü©ó­n¥h°£¿ß¤ò§Ü­ì¡A¥Î¶Ç²Î©Ù¥¬ªº®ÄªG­n¤ñ¥Î§l¹Ð¾¹ÁÙ­n°ª¥X3­¿¡C
¤@¨Ç¬ã¨sÅã¥Ü­¹ª«¥i¯à¦b¤@¨Ç±wªÌ¨­¤W¡A·|»¤µo²§¦ì©Ê¥Ö½§ª¢©Î¨Ï¯gª¬´c¤Æ¡A¦¹ºØ±¡§Î¤×¨ä¦b2·³«eÀ¦¥®¨à¨­¤W·|²£¥Í¡A¤@¯ë¦Ó¨¥¡A²§¦ì©Ê¥Ö½§ª¢¯gª¬·UÄY­«¡A¤p«Ä¦~ÄÖ·U¤p¡A­¹ª«ªº¨¤¦â¥i¯à·U©úÅã¡A­¹ª«¹L±Ó¥i¯à¤Þµo¥Ö½§Äo¯l¥~¡A¤]¥i¯à¥X²{¸¡µh¡B¹Ã¦R¡B¸¡Âmµ¥®ø¤Æ¹D¯gª¬¡A¤Î»ó¶ë¡B¥´¼QÀ¡¡B­ý³Ýµ¥¤W©I§l¹D¯gª¬¡C¦Ó¦b¸û¤jªº¤p«Ä¡A¥Ö®hªÞ­Mµßªº¨¤¦â¤]³Q´£¥X¡C

³Ì±`¤Þ°_¹L±Óªº­¹ª«¬O³J¡B¥¤¡Bªá¥Í¡B³Á¡B¶À¨§¤Î³½½¼ÃÉ¡A¨ä¦¸¥i¦Ò¼{Ä«ªG¡B°¨¹aÁ¦¡B­JÅÚ½³¡B¤j°©´ö¡C¤]¦³¬ã¨s«ü¥X¤p«Ä¥X¥Í¡A­÷¨Å«ùÄò3-4­Ó¤ë¥H¤W¥i¯à¨¾¤î¹L±Ó¡A¥D­n¬O¦]¬°¥À¨Å¦³§U©ó¸z¹D¤ºÂùª[±ìµß(¤ñµá¦hµßbifidobacteria¡A«UºÙABµß)¤Î¨Å»Ä±ìµß(lactobacilli)ªº¥Íªø¡A¥i«P¨Ï²Ä¤@«¬T²Ó­Mªº¦¨¼ô¡A¦ý«e3­Ó¤ë¥À¨Åªº«OÅ@®ÄªG¡A¥uºû«ù1¦~¡A¨ì2·³®É¤wµL®t²§¡C¦ý¬O¦pªG¥À¿Ë¦³¹L±ÓÅé½è®É¡A¦bÃh¥¥¥½´Á¤Î­÷¨Å´Á¶¡À³ÁקK­¹¥Î¤W­z¹L±Ó­¹ª«¡C¦ý¤]¦³¬ã¨s«ü¥X¦b¥X¥Í9­Ó¤ë¤º´NÁý­¹³½¦³§U©ó¹w¨¾¡A¦P¼Ëªº®ÄªG¤]µo²{®a¤¤¾i¤p³¾¤]¦³À°§U¡C¤p«Ä¥X¥Í«e¸z¹D¬OµLµßªº¡A¥Í²£¤è¦¡¨M©w¤F¥X¥Í¤@¤Ñ¤ºªºµßºØ¡A¤§«á«h¦]Áý­¹¥À¨Å»P§_¦Ó¼vÅT¡C

¥t¦³¬ã¨s«ü¥X­««×±wªÌ»P¤¤«×±wªÌ¬Û¤ñ¡A°£IgE¼W¥[¤ñ¨Ò°ª¨Ç¥~(92% vs 83%)¡A¹ï¿ß¤ò¡B¹ÐÂÚ¡BMalassezia sympodialis¤Îª÷¶À¦â¸²µå²yµß¹L±Ó²v¤]¸û°ª¡A¦ý¹ï©óGRASS POLLEN¹L±Ó²v«h¨S®t(PLOS ONE 2016)¡C


¸z¯qµßªº¬ã¨s©l¦Û2001¦~ªºLancetÂø»x¡A(Lancet 2001;375(9262):1076-9)¡A¨Ï¥Îªº¬OLactobacillus rhamnosus (Lactobacillus GG) strain 53103¡A¥Î¶q¬°¨C¤Ñ100»õ(10ªº10¦¸¤è)CFUªº½¦Ån©óÃh¥¥³Ì«á2-4©P¥¥°ü§]­¹¡A²£«á¦A¥Ñ¥¥°ü©Î·s¥Í¨àªA¥Î6­Ó¤ë¡C¥Ø«e¤@¯ë¨Ï¥Îªº¸z¯qµß¦³¤TÄÝ¡A¦Ü¤Ö¥]¬ABifidobacteria infantis, Streptococcus thermophilus,  Bifidobacteria bifidus,  Bifidobacteria longum (BL)Bifidobacteria lactis¤ÎLactobacillus GG¡BLactobacillus rhamnosus ¡BLactobacillus reuteri ¡C¦b2001¦~¤À§O¥ÑGdalerich¤ÎBelarusªº¬ã¨s¤¤(Probit trial)¡A³£µo²{¸z¯qµß¥i¤U­°²§¦ì©Êµo¥Í²v¬ù4¦¨¡C²§¦ì©Ê±wªÌªº¸z¹D¤¤¡A¸g¥Ñ¤ÀªRÁT«K¡A¥iµo²{¦³¸û¦hª÷¶À¦â¸²µå²yµß¡A¦ÓÂùª[±ìµß¸û¤Ö¡AWestonµ¥¤H¥HLactobacilli fermentum VRI-033 PCCµ¹¤©6¨ì18­Ó¤ëªº²§¦ì©Ê±wªÌ¡Aµo²{¨ã¦³§ïµ½²§¦ì©Ê¯gª¬ªº®ÄªG¡C¥t¤@½g¬ã¨s¹ï¤û¥¤¹L±ÓªÌ¡A¨Ï¥ÎLactobacillus GG (LGG, Lactobacillus rhamnosus) 4¶g¡A»P¦w¼¢¾¯¬Û¤ñ¡A¥i´î»´±wªÌ¥Ö½§¯gª¬¡CÁÙ¦³¤@½g¹ï¥¥°üÃh¥¥¤Î­÷¨Å´Áµ¹¤©Lactobacillus GG¡A¤]µo²{¥i¥H´î½w²§¦ì©Ê·Ã¯lµo§@ªº¦~ÄÖ¡C°£ª½±µªA¥Î¸z¯qµß¥~¡A¤]¥i¥HÂǪA¥Î¯S®í­¹ª«¦Ó«P¶i¸z¯qµßªº¥Íªø¡AºÙ¬°prebiotics¡C¥À¨Å¤¤ªºprebiotic«D³æ¤@ª«½è¡A»P¥À¨Åªº³J¥Õ½è¤ÎÁC§t¶q¸û§C¦³Ãö¡A¥t¥~©Ò§tªº¨ÅÅK³J¥Õ( lactoferrin)¡B¨Å¿}( lactose), ®Ö苷»Ä(nucleotides)¤Î¹è¿}( oligosaccharides)³£¦³Ãö¡A¸û½T©wªº¬O¨ä¤¤«D®ø¤Æ©Ê¹èÁÞ¡A¦pFructo-oligosaccharides ¤Îtrans-beta-galacto-oligosaccharides¦]¤p¸z®ø¤Æ§l¦¬¦³­­©Ò¥H¥i¶i¤J¤j¸z¦Ó«P¶ibifidobacteriaªº¥Íªø(bifidogenic effect)¡C
¤£¹L¨Ã«D©Ò¦³¬ã¨s³£»{¬°­÷¨Å¥i¹w¨¾²§¦ì©ÊÀã¯l¡A¤]¦³¬ã¨sµo²{·í¤÷¥À¿Ë³£µL¦¹Åé½è®É¡A¥uÁý¥À¨Å¶W¹L¥|­Ó¤ë¤p¨à¤Ï¦Ó®e©ö²£¥Í²§¦ì©ÊÀã¯l¡C¥t¥~¦b·ç¨å¹ï8300¤Hªº°Ý¨÷½Õ¬d¤¤¡A¤]µo²{«ùÄò¥À¨Å1¦~¡A¹ïµo¥Í²§¦ì©Ê¥Ö½§ª¢¤ñ¨Ò¨ÃµL¤U­°¡A§ó¦³¬ÆªÌ¡A¯Ã¦èÄõ¹ï¥X¥ÍÅé­«¸û»´ªÌ¡A¤ñ¸û¥À¨Å¤Î¤£´¿Áý¥À¨Åªº¤p«Ä¡Aµo²{Áý­¹¥À¨Å6­Ó¤ë¤º¡A²§¦ì©Êµo¥Í²v¬°6.13­¿¡A¦Ó¶W¹L6­Ó¤ë¬Æ¦Ü°ª¹F9.70­¿¡C¦Ü©ó¨Ï¥Î¤ô¸Ñ³J¥Õ¡A¼w°êªºGINI¬ã¨s¡A¦pªG¥u¨Ï¥Î¤ô¸Ñ¹T³J¥ÕÁý­¹12­Ó¤ë¡A²§¦ì©Êµo¥Í²v¤U­°58%¡A¨Ï¥Î³¡¤À¤ô¸Ñ¤p³Á³J¥Õ«h¤U­°44%¡C¦ý³Ìªñµoªíªº¥t¤@¶µ¬ã¨s(Clin Exp Allergy 2006:36:899-906)¹ï5·³¥H¤U¤wµo¯f¤§¥®¨àÁý­¹§t¤ô¸Ñ³J¥Õ¤ÎLactobacillus rhamnosus©ÎLactobacillus GG (LGG)¸z¯qµß3­Ó¤ë¡A¨Ã¥¼µo²{®ÄªG¡C³Ì·sµoªí©ópediatric 121/4, 2008, e850-856ªº¬ã¨s¤£¥u¨S®ÄÁÙ·|¼W¥[¹L±Ó©Ê¤p®ðºÞª¢¡C¦P¼Ëµ²ªG¡A·s¥[©Y¤]³ø§i¸É¥R²§¥Íµß¤@¦~¨ÃµLªk´î¤ÖÀ¦¨àÀã¯l²£¥Í(Clinical & Experimental Allergy, 2009 (39) 571-578.)¡C¤£¹L¸z¯qµßªºÀø®ÄÅãµM¦b¥i¹w¨£ªº¥¼¨Ó¤´·|¬O¤£Â_ª§Ä³ªº¸ÜÃD¡A¦b°Ó·~ªº¦Ò¶q¤U¡A¦³®Äªº¤å³¹¥i¯à³Q¹Á¸Õ³ø§iªº¾÷·|·|¸û°ª¡A¤@¯ë®aªø¦pªG³ß¹Á¸Õ¥H¸z¯qµß§@¬°ªvÀø¡AÀ³¸Ó¥H2¤ë°µÆ[¹î´Á¡A¦pªG¦P®É¦X¨Ö¦³¸z­G¯gª¬¡A¦p®e©öµÈ®ð¡B¸¡ÂmªÌ¡AÀu¥ý¦Ò¼{¾A¥Î¡C

°£¨ë¿E¤Î¹L±Ó¥~¡A±¡ºü¡A¥Ö½§·P¬V¤Î·Å«×¡B®ð­Ô³£·|»P²§¦ì©Ê¥Ö½§ª¢¦³Ãö¡AÀ£¤O¡B¼««ã¡Bªq³àµ¥±¡ºü¡A³£¥i¯à¨Ï²§¦ì©Ê¥Ö½§ª¢´c¤Æ¡A¤H»Ú°ÝÃD©Î­«¤j¥Í¬¡¨Æ¥ó¡A¦pÂ÷±B¡B´«¤u§@©Î¿Ë¤H¦º¤`³£·|¨Ï¯e¯f´c¤Æ¡A¦b­Ó¤H²M¼ä³Q¹L«×±j½Õªº¤µ¤Ñ¡A²M¼ä«á¦pªG¤£¥ß§Y«O·Ã¡A¤]¬O±`¨£²§¦ì©Ê¥Ö½§ª¢´c¤Æ¦]¯À¡A¨ä¥L¦]¯ÀÁÙ¥]¬A¥V¤Ñ©u¸`°®Àê¡B©Î©~¦í¦b°®Àê¦a°Ï¡A«Ç¤º·x®ð©Î¹q¼ö¾¹¡A¼ö¤ô¾þ©Î¨N¯D®É¶¡¹L¤[¡C¦³¨Ç¤H«h·|¦b¬~¤T·Å·x«á´c¤Æ¡C³Ì«á¡A²Óµß·P¬V¤]¬O±`¨£²§¦ì©Ê¥Ö½§ª¢´_µo©Î´c¤Æ¦]¯À¡A¦pªG±wªÌªº²§¦ì©Ê¥Ö½§ª¢¦³¬ðµM´c¤Æ®É¡A·P¬V¤]¬O¤£¥i©¿²¤¦]¯À¡A¦ý²Óµß°£¤F·P¬V¥~¤]¥i¯à§@¬°§Ü­ì¡B¶W¯Å§Ü­ì©Î³z¹L¬¡¤ÆToll¨üÅé¦Ó¤Þ°_Àã¯l´c¤Æ¡C¯f­ìµßªº¦s¦b³¡¥÷¥u¬Oªí­±¦Ã¬V¡A¥ÎÃþ©T¾J®øª¢ÃĪ«¤@¼Ë¦³®Ä¡A¦pªG¤w½T¹ê¦³·P¬V¯gª¬©Î¥X²{¥Ö½§Áw疱¡A¦¹®É¥i¥H¨Ï¥Î§Ü¥Í¯À¡A©Î¬O¨Ï¥Î¥~¥Î§Üµß¾¯¡C¶Ç²Î¤W¬O¨Ï¥Î¤fªA§Ü¥Í¯À¡A¥~¥Î§Üµß¾¯«h¥ÎµµÃĤô¡A¥Ø«e¦³¬ã¨sµo²{¹j©]¨Ï¥Î§t»È¦çª«(Padycare)¡A¤@¼Ë¥i¥H¹F¨ì´î¤Öª÷¶À¦â¸²µå²yµß¨Ã§ïµ½¥Ö½§·Ã¯l¯gª¬¡C
 
²§¦ì©Ê¥Ö½§ª¢ªºªvÀø
¹ï©ó¹³²§¦ì©Ê¥Ö½§ª¢³o¼ËªººC©Ê¯f¡A«Ø¥ß¨}¦nªºªºÂå®v¡B¯f±w¡B®aÄݪº¤T¤èÃö«Y¡A¤Q¤À­«­n¡AÂå®v¤@¯ë·|¨Ì¾Ú¯f¤Hªº¦~ÄÖ¡BÄY­««×¤Î¾ãÅé°·±d±¡§Î¦Ó§@¥XªvÀø«Øij¡C¦ýªvÀøµ²ªG¡A­nµø¯f±w©Î¨ä·ÓÅ@¤§®aÄݬO§_¯u¥¿¯à°t¦XÂå®vªº«ü¥Ü°õ¦æ¦Ó©w¡A¨Ã­nª`·N¨ì­þ¨Ç¦]¯À¬O¹ï±wªÌ¦³¯q©Î¦³®`ªº¡C¦h¼Æ±wªÌ¸g¹L¾A·íªº¥Ö½§·ÓÅU¤Î§ïµ½¥Í¬¡¤è¦¡¡A²§¦ì©Ê¥Ö½§ª¢´N·|¦³©Ò¶i¨B¡C
²§¦ì©Ê¥Ö½§ª¢ªº³B²z¡AªvÀø¤Î¹w¨¾´c¤Æ¦Pµ¥¥D­n¡A³o»Ý­n¦³¨}¦nªº¥Ö½§«O¾i²ßºD¡A¨ÃÁקK¨ë¿E¤Î¬¡¤Æ§K¬Ì¤ÏÀ³¡A»¤µoÄo¤Î·k§ì´`Àô¡A±wªÌ¤Î®aÄݤ]­n²Ó¤ßÆ[¹îªvÀø®É¥Ö½§ªºª¬ºA¡A§ä¥X³Ì¦w¥þ¦³®ÄªºªvÀø¤è¦¡¡C
²§¦ì©Ê¥Ö½§ª¢ªºªvÀø¡A¥D­n¦b¥H§K¬Ì§í¨î¾¯®øª¢(¥]¬AÃþ©T¾J¡B¤Î·sªº§K¬Ì½Õ¸`¾¯)¡B¤îÄo¤Î±±¨î·P¬V¤T¤è­±¡CÃþ©T¾J¥~¥Î¦Ü¤µ¨Ï¥Î¶W¹L50¦~¡A¤´µM¬O¬°ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº¥D¤O¡A¦ý·sªº§K¬Ì½Õ¸`¾¯´¶¯S¥Ö(protopic)¤ÎÂå¥ß§´(Elidel)¤]³vº¥´¶¹M¨Ï¥Î¡A³o¨ÇÃÄ«~¡A¤£·|¦³Ãþ©T¾Jªº¥Ö½§µäÁY°Æ§@¥Î¡A¦ý¦³¤Ö¼Æ¤H·|²£¥Í¶î©Ù®É¨ë¡BÄoµo¬õ²{¶H¡A¯S§O¬O¨Ï¥Îªì´Á¡A³o¨Ç§K¬Ì½Õ¸`¤£¥u¥i¥H´î¤Ö²§¦ì©Ê¥Ö½§ª¢´_µo¡A¤]¥i¥H´î¤Öªø´ÁªºÃþ©T¾J¨Ï¥Î¡A¦ý¤´µLªk¥þ­±¨ú¥NÃþ©T¾J¡C¥t¥~¥Ñ©ó¨Ï¥Î¸gÅ礣ªø¡A©Ò¥H¥Ø«e¥u«Øij¦b2·³¥H¤W¨Ï¥Î¡C2005¦~3¤ë¡A¬ü°êFDA°ò©ó¹s¬PÁ{§É­Ó®×¤Î°Êª«¬ã¨s¡A¹ï¦¹Ãþ·sªº§K¬Ì½Õ¸`¾¯µo¥X­PÀùĵ°T¡A¥D­n¬O²O¤Ú½F¤Î¥Ö½§Àù¡A¦]¦¹¦¹ÃþÃÄ«~¤´«Øij§@¬°¤G½uÀøªk¡C
Ãþ©T¾J¨Å»I¤Îªo»I¬O¥Ø«e²§¦ì©Ê¥Ö½§ª¢ªvÀø¥D¤O¡A¨Æ¹ê¤W¦h¼Æ¨ä¥L·Ã¯l¤]¬O¨Ï¥ÎÃþ©T¾J¨ÓªvÀø¡AÃħ½¤¤©ÒÁʱoªvÀøÀã¯lªºÃĺޤ¤¤]´X¥G³£§t¦³Ãþ©T¾J¡C¥~¥ÎÃþ©T¾J¨Ì±j«×¤À¬°7¯Å¡A¸û®z®ÄªºÃþ©T¾J¬Û¹ï¨Ï¥Î¦w¥þ¡A¦Ó±j®Ä¤Î¶W±j®ÄªºÃþ©T¾J«hÀ³¥Ñ¥Ö½§¬ìÂå®v³B¤è¡A¦Ü©ó­n³B¤è¦óºØ±j«×¡A¦óºØ¾¯«¬ªºÃþ©T¾J¡A«h­n¨Ì±wªÌ¦~ÄÖ¡B³¡¦ì¡BÄY­««×¤Î±wªÌ²ßºD¦Ó©w¡A¨Ï¥Î®ÉªºµÎ¾A·P¤]«Ü­«­n¡A¦]¬°¦³¨Ç±wªÌªº¥Ö½§·|¹ï¬Y¨Ç¾¯«¬©Î¦¨¤À²£¥Í¤£¾A²{¶H¡Aªø´Á«ùÄò¨Ï¥ÎÃþ©T¾J·|¾É­P§½³¡¥Ö½§ÅÜÁ¡©ö·P¬V¤Îµõ¯¾¡C¦pªG¤j¶q¨Ï¥Î±j®ÄÃþ©T¾J¡A¦p¤@¤Ñ¨Ï¥Î¤j©ó5¤½§J¡A·|¤zÂZ°©Àf¤Î¤º¤Àªc¡A¦b¤p«Ä¥i¤Þ°_¥Íªø¿ð½w¡C
·í¥~¥ÎÃþ©T¾JµL®Ä©Î¶î©Ù¾¯¶q¤Ó¤j®É¡AÃÄ®v«K¥i¯à·|³B¤è¤fªAÃþ©T¾J¡A¦³®É¬Æ¦Ü·|¦Ò¼{ª`®g¤è¦¡¡A¨ä¤¤³Ì±`¥Îªº¤fªA²£«~¬Oprednisolone¡A¦Óª`®g¾¯«h¬Okenacort¡A¦ý¦]¥þ¨­©ÊÃþ©T¾Jªº¥i¯à¶Ë®`¡A°£¥Ö½§¥~¡A¤]·|¤Þ°_°©Àf²¨ÃP¡B°ª¦åÀ£¡B°ª¦å¿}¡B¥þ¨­©Ê·P¬V¡B¥Õ¤º»Ùµ¥¡A¦]¦¹¥u¯àµu´Á¨Ï¥Î¡C¦ý¦]Ãþ©T¾J¬ðµM°±ÃĤ]·|¦³¯f±¡´c¤Æ²{¶H¡A¦]¦¹¦pªG¤w¸g¨Ï¥ÎÃþ©T¾J¤@¬q®É¶¡«á­n°±ÃÄ¡A¥²¶·­n¤p¤ß³vº¥´îÃÄ¡C
·í¦³²Óµß·P¬V®É¡A«h»Ý­n¥Î§Ü¥Í¯À¡A¥i¥H¥Î¥~¥Î©Î¤fªA¤è¦¡¶i¦æ¡A¥~¥Î¸û¬°¦w¥þ¡A¦ý¤fªAÀø®Ä¸û¨Î¡C¤£¹L¦b¹êµýÂå¾Ç¬ã¨s¤¤¡A¥~¥Î¤G¦X¤@ÃÄ»IªºÀø®Ä¤£¤ñ³æ¥ÎÃþ©T¾J¦n*¡C¤£¥u²Óµß¡AÅðµß¤Î¯f¬r·P¬V¦b²§¦ì©Ê¥Ö½§ª¢¤]·|¼W¥[¡A»Ý­n¥t¥~ªº§ÜµßªvÀø¡C
 ¤fªA§Ü²Õ´Ói¬O¥Ø«e±`¥Îªº¤îÄoÃÄ«~¡A¶ÝºÎ¬O³Ì¤jªº°Æ§@¥Î¡A¦b¤p¨à¨Ï¥Î«h»Ý¯S§Oª`·N¤ß«ß¤£¾ãªº°ÝÃD¡C§Ü²Õ´Ói¤îÄo¥i¯à¬O¥D­nªº®ÄªG¡C§Q¥Î³oºØ®ÄªG¡AºÎ«eªA¥Î¡A¥i¥HÀ°§UºÎ¯v¡A¤]¦]¦¹¥i¥H´î»´¦]¬°ºÎ®É·k§ì¦Ó¤Þ°_ªº²§¦ì©Ê¥Ö½§ª¢´c¤Æ¡C
 °£¤F§Ü²Õ´Ói¡A¥Ø«e¥«­±¤W¤]¦³¥Õ¤T²m¨üÅé«ú§Ü¾¯¦pmontelukast (Singulair)¤ÎZafirlukast (Accolate)¡A«eªÌ¥Î©ó6·³¥H¤W®ð³Ý±wªÌ¡A«áªÌ«h¥Î©ó²M¤Ö¦~¤Î¦¨¤H®ð³Ý¤Î²§¦ì©Ê¥Ö½§ª¢¡A¦ý¹ï²§¦ì©Ê¥Ö½§ª¢Àø®ÄÁö¦³¦ý¦ü¥G¤£¦p¹w´Á¡C

 ÄY­«ªº¦¨¤H²§¦ì©Ê¥Ö½§ª¢±wªÌ¡A°£¥þ¨­©ÊÃþ©T¾J¥~¡A¤]¥i¯à·|¨Ï¥Î¨ìÀôÌUÅð¯À(Cyclosporine)¡BMethotrexate (MTX)©Îazathioprine µ¥§K¬Ì§í¨î¾¯¡A³o¨ÇÃÄ«~¤@¯ë¥Î©ó¶Ç²ÎªvÀøµL®Ä®É¡A¥i¥H§í¨î§K¬Ì²Ó­Mªº²£¥Í¤Î§@¥Î¡A¨ä¤¤ÀôÌUÅð¯À¥i¥H»¡¬O¥Ø«e¼s¨ü­«µøªº¥~¥Î§K¬Ì§í¨î¾¯Protopic¤ÎElidelªº»ó¯ª,Methotrexate (MTX)©Îazathioprine ¦b¤@¶µ12©PªºÁ{§É¸ÕÅç¤ñ¸û¤¤Àø®Ä°ò¥»¬Û¦P¡A°Æ§@¥Î¤ñ¨Ò¬Ûªñ¡A¦ýazathioprine¸û©ö¤Þ°_¥Õ¦å²y¤U­° ¡C¤fªAÀôÌUÅð¯À¥i¤Þ°_°ª¦åÀ£¡Bäú¤ß¡B¹Ã¦R¡BÀYµh¡B¨ë³Â¤ÎµÇ¥\¯à¨ü·lµ¥°Æ§@¥Î¡A¤]¥i¯à¤Þ°_Àù¯g¤Î¼W¥[·P¬V¤§¥i¯à¡A¦ý¦pªG¤ñ¸û¦¹ÃÄ6©P(3-4mg/kg/d)¤ÎÃþ©T¾J2©P(0.5mg/kg/d)ªvÀø¡A¤fªAÀôÌUÅð¯À°±ÃÄ«á¸û¯à¤Þ°_½wÂà(Schmitt J µ¥¼w°ê¾ÇªÌ)¡C¤]¦³¬ã¨s¬O¥H¸û§Cªºcyclosporine¾¯¶q(2mg/kg/d)¨Ö¥Î¸²µå¿}Ói(25mg/gm/d)¨ÓªvÀø¡C¦ý¦]¬°°±ßӫᦳ²§¦ì©Ê¥Ö½§ª¢´_µoªº°ÝÃD¡A¦]¦¹³o¨ÇÃĪ«»P¥þ¨­©ÊÃþ©T¾J¤@¼Ë¡A³£¥u¾A¥Î¦bÄY­«±wªÌµu´Á¨Ï¥Î¡A¥BÀ³¥Ñ±MªùªvÀøªºÂå®vµ¹¤©¡CªvÀø®É¡A¤]­nºÉ¤O§ä¥X±wªÌ²§¦ì©Ê¥Ö½§ª¢´c¤Æªº»¤µo¦]¯À¡A¨Ã´M¨D¨ä¥LªvÀø¤è¦¡¡A¦³®É±wªÌÁÙ¥i¯à»Ý­nµu´Á¦í°|ªvÀø¡C
 
·Ó¥úÀøªk
¦X¨Ö©Î³æ¿W¨Ï¥Îµµ¥~½uA©ÎB¡A¦b¸û¤jªº¤p«Ä(>12·³)¤Î¦¨¤H¡A¤]¬O»´¨ì¤¤«×²§¦ì©Ê¥Ö½§ª¢¦³®ÄªºªvÀø¤è¦¡¡A¹ï©ó§ó¹x©Tªº±wªÌ¡AÁÙ¥i¥H¦A¥[¤W·P¥ú¾¯(psoralen)¶i¦æ©Ò¿×¡u¥ú¤ÆÀøªk¡v¡A¥ú·ÓÀøªk¥i¯à¨Ï¥Ö½§´£«e¦Ñ¤Æ¡A¤Î¦³¼ç¦b¥Ö½§Àùªº¥i¯à¡A©Ò¥H·íÂå®v¤Î±wªÌ¿ï¾Ü¥H¥ú·ÓªvÀø®É¡A»Ý­n±K¤ÁºÊ·þ¨Ã¨Ï¥Î³Ì¤Ö¦ý¦³®Äªº¥ú·Ó¾¯¶q¡C¥t¥~·sªº¶WªøªiUVA!¹ï©ó«æ©Ê±wªÌ¦³¤£¿ùÀø®Ä¡A¦Ü©óºC©Ê±wªÌ«h«Øij¥Î311nm¯¶ªiUVB¡C¤@¥÷¼w°ê¬ã¨sÅã¥Ü6­Ó¤ëªº¼ÒÀÀ¦º®üÀô¹Òªº®ûªw¥úÀø(balneophototherapy)®ÄªGÀu©ó311nm¯¶ªiUVB
 
¥Ö½§·ÓÅU (JEEADV 200923:751)
À°§U¥Ö½§Â¡¦X¡Aºû«ù¥Ö½§¦b°·±dª¬ºA¡A¬O¹w¨¾¥Ö½§¶i¤@¨B¶Ë®`¤Î¼W¶i¥Í¬¡«~½è«Ü­«­nªº¡Cµo®i¥X¤@®M¨Ò¦æªº¤é±`¥Í¬¡·ÓÅU¤è¦¡¡A¨Ã½T¹ê¿í¦u¡A¬O¨¾¤î²§¦ì©Ê¥Ö½§ª¢´_µoªºÃöÁä¡C¦b2·³«e¤p«ÄIgE±`§e¥¿±`¡A¦]¦¹¦³¾ÇªÌ±À´ú¥Ö½§§¹¾ã©Ê¨ü·l¤Þµo¹L±Ó­ì¶i¤J¥Ö½§¡A¤~¤Þ°_Á{§É¯gª¬¡A¤]¦]¦¹¥®¨à®É¨}¦nªºÅ@½§¤Q¤À­«­n¡C(J Allergy Clin Immunol 2006 July)
 ¥Î·Å¤ô¬~¾þ¥i¥H¸É¥R¤ô¤À¡A¦Ó¤£·|¨Ï¥Ö½§¹L«×°®Àß¡C¥Ñ©ó¨mÆP·|¨Ï¥Ö½§°®Àß¡A©Ò¥HÂå®v¥i¯à·|«Øij¨Ï¥Î¸û·Å©MªºªÎ¨m©Î«Øij¨Ï¥Î¤£§t¨mÆPªº²M¼ä¾¯¡CÀ¦¨àªo¤Î¨N¯Dªo«h¤@¯ëÀ°§U¤£¤j¡Cªñ¨Ó¬ã¨sµo²{¥Hº}¥Õ¾¯¥Î·Å¤ôµ}ÄÀ¨ì¦w¥þ¤£¨ë¿E¥Ö½§ªº¿@«×¡A¦b¸Ëº¡¤ôªº¤@¯ë¤j¤p¡]¬ù152¤½¤É¡^ªº¯D¬û¤º¡A¥[¤J¥bªM¥«­±¤W¿@«×0.06¢Hªº®a¥Îº}¥Õ¤ô¡A¤]´N¬O0.005%ªº§C¿@«×¡AÀV³¡¥H¤Uªº¨­Å鳡¦ì¡A¤@­Ó¬P´Á¿ï¨â¤Ñªw¾þ¡A¨C¦¸ªw5¨ì10¤ÀÄÁ¡C¸g¹L¤@­Ó¤ë¡A·|¬Ý¨ì²§¦ì©Ê¥Ö½§ª¢ªº¯l¤l­±¿nÅܤ֡BÄY­««×¤]­°§C¡C¦pªGªw¤T­Ó¤ë¡A¶i¨B·|§ó©úÅã¡C
 ¬~¾þ«á¡AÀ³Åý¥Ö½§µy·L­·°®©Î»´»´©ç°®¡£À³ÁקK¥Î¤O¼¯À¿©Î«æ³t§j°®¡¤«á¡A¥ß§Y¨Ï¥Î¼í·Æ«O·Ã¾¯¥H±N¤ô¤À¯d¦b¥Ö½§¤W¡C
 °£¤F«O·Ã¥~¡A¼í·Æ«O·Ã²£«~¤]¥i¥H¥[³t¥Ö½§Â¡¦X¡A¨ó§U¥Ö½§»Ù¾À«Ø¥ß¥H¨¾¤î¶i¤@¨B¨ë¿E¤Î°®Àê¡C§t¤ô¶q¤Ó°ª©Î§t°sºë¦¨¥÷ªº¨Å²G»]µo¸û§Ö¡A¥B°sºë¥i¯à¨ë¿E¥Ö½§¡A¦]¦¹¨Ã«D³Ì¨Î¿ï¾Ü¡C¨ÅÁ÷©Îªo»I¾¯«¬¦bÀ°§U¥Ö½§Â¡¦X¤W®ÄªG¸û¨Î¡C¦b²£«~¬D¿ï¤W¡A¶Ç²Î¤W¥H¤Z¤hªL©Î§¿¯À(urea)¡A¦ý¦]¤Z¤hªL¸û¬°ªo¿°¦Ó§¿¯À³¡¥÷±wªÌ·|¨ë¿E¡A¦b¸gÀÙ³\¥i¤U¤]¥i¬D¿ï¥Hceramide¬°¥Dªº«OÀ㾯¡A³Ìªñ¬ü°ê¤]®Ö­ã¨âºØ¯S®í«OÀ㾯¤W¥«ªvÀø²§¦ì©Ê±wªÌ¡A¤À§O¬OAtopiclair¤ÎMimyx (Physiogel A.I.)¡A¤À§O§t¦³¥Ì¯ó¦¸»Ä¡Bshea butter¤Îpalmitamide MEA¡A¦ý§¡¬Û·í©ù¶Q¡A«eªÌ¨C¤Ñ»Ý¥Î3¦¸¡A¦Ó¨C¤½§J­n»ù¬ù¥x¹ô26¤¸¡C¸û¤pªº¤p«Ä¿ï¥Î«OÀ㾯®É¡AÀ³ÁקK¶Ç²Î¿P³Á¦¨¤À¡A¥H¤Î§t¦³ªá¥Í¦¨¤À¡A¥t¥~¤]¦³³ø§i§t¦³shea butter¦¨¥÷¥i¯à»Platex, banana, avocado, chestnut, kimi¥æ¤¬¹L±Ó¡C¦Ü©ó¨Å²G¸òÃÄ«~¦óªÌ­n¥ýÀ¿¡A¬ã¨sµ²ªG¦ü¥G­þºØ¥ýÀ¿³£µL§«(doi: 10.1111/pde.12758.)
 ¦b«O·Ã¤Î­×´_¥Ö½§¤W¡A¥t¤@­«ÂI¬O¹w¨¾¥Ö½§·P¬V¡A¥Ö½§·P¬Vªº¯gª¬¥]¬A¤pÁw疱¡Bº¯²GªºµõÁ_©Î»Äµh¡A¥H¤Î¶À¦â¯m¥Öªº¤p¤ôªw¡A¦pªG³o¨Ç¥Ö½§·P¬Vª¬¥X²{®É¡AÀ³ºÉ³t´NÂåªvÀø¡C

¹w¨¾¹L±Ó­ì
Âå®v¥i¯à·|«Øij´î¤Ö±µÄ²¥i¯àªº¹L±Ó­ì¡A¨Ò¦p¹ÐÂÚ¹L±Ó»Ý­n±N§É¹Ô¡BªEÀY¥H¯S®í¨¾¹Ð®M¥]»q¡A±`¥Î¼ö¤ô²M¬~§É³æ¤Î¥á±¼¦a´à¡C¦ý¥Ø«e¹ï©óªÅ®ð¶Ç¼½ªº¹L±Ó­ì¡A¨ÃµLªk¥ÑÀô¹Ò¤¤¥þ­±¥h°£¡C¯S®í¨¾¹Ð®M¶È¤Ö¼Æ¬ã¨s»{¬°¦³®Ä¡A¦h¼Æ¬ã¨sµo²{»P¤@¯ë´Ö½èªEÀY®M¨ÃµL®t²§¡A¶Ô¬~¤ñ¸û­«­n¡C¬Æ¦Ü¦³­^°ê¤@¥÷8¦~ªº°lÂܬã¨s¡Aµo²{¦­´Á(¥X¥Í8¶g)±µÄ²¹ÐÂÚªº¼ÉÅS°ª§C»P¤§«á²£¥Í²§¦ì©ÊÀã¯lµLÃö¡A¬Æ¦Ü°ª¼ÉÅSªÌµo¥Í²v¤Ï¦Ó§C¡C(Harris JM, BJD 2007, 156:98-704)
 §ïÅܶ¼­¹¹ï©ó´î»´²§¦ì©Ê¥Ö½§ª¢¯gª¬¤]¨Ã«D³£¦³®Ä¡A¤£¹L·í¯f¥v¡B¹êÅç«ÇÀˬd¤Î¯S©w¯gª¬³£±j¯PÃhºÃ­¹ª«¹L±Ó®É¡A§ïÅܶ¼­¹©Î³\¦³¯q¡C³Ì±`¨£ªº¤è¦¡¬O¨Ï¥Î¤ô¸Ñ¥¤¯»¡B¤Ö¦Y®üÂA¤Î¤Ö¦Y³J¥Õ¡C2-82%ªº²§¦ì©Ê¥Ö½§ª¢±wªÌ¡A¦b¥H¯S©w­¹ª«§ë¤©«áÀã¯l´c¤Æ¡C¤@¶µ°ê»Ú¬ã¨s¤¤¡A¹ï721601¦ì±wªÌ¡Aµo²{ªA¥Î½\Ãþ¡B¾ý¯»¡B½­µæ¤Î¾ñÆVªo¸û¦hªÌ¡A¯gª¬¸û»´·L¡A¦Ó¶À¨§ªo«h¦³¤Ï®ÄªG¡C¨ä¥L¦pÂæªo¡Bµo»Ã¶À¨§»s«~¡B¥©§J¤O¡B¨Å¹T¡B©@°Ø¡BÀu®æ¡A¤]¦³¤£¨}¼vÅT¡C¤@¯ë±`«Øij¥X¥Í6­Ó¤ë«á¦Aµ¹¤©©TºA­¹ª«¡A¹ï©ó°ª¦MÀI¸s¡AÂû³J¡Bªá¥Í¡B°íªG¤Î³½¡A¨ì2¨ì3·³«á¤~µ¹¤©¡C¤£¹L¦bZutavernªº¬ã¨s¤¤¡A¤Ï¦Óµo²{¤Ó±ßµ¹¤©³J¡B¥¤¡A¤Ï¦Ó·|¼W¥[²§¦ì©Ê¥Ö½§ª¢ªºµo§@¾÷·|(¤À§O¼W¥[60%¡A70%)¡C±wªÌ¡B®aÄݤÎÂå®v»Ý¦@¦P¨M©w¶i¦æ¶¼­¹­­¨î¬O§_±o·í¡A°£«D¥ÑÂå®v¡BÀç¾i®v¥¿½TºÊµø¡A§_«h¹L¦hªº¶¼­¹­­¨î¥i¯à¤Þ°_ÄY­«ªºÀç¾i»Ùê¡A¯S§O¬O¦b¤p«Ä¨­¤W¡C
 
²§¦ì©Ê¥Ö½§ª¢»P¥Í¬¡«~½è
ÁöµM²§¦ì©Ê¥Ö½§ª¢·|¤Þ°_³\¦h¯gª¬¡A¦ý±wªÌ¤´µM¥i¯àºû«ù¨}¦nªº¥Í¬¡«~½è¡A­n¹F¨ì¦¹¤@¥Ø¼Ð¡A±wªÌ»Ý­n¹ï²§¦ì©Ê¥Ö½§ª¢¦³¨}¦nªº»{ÃÑ¡C²M·¡²§¦ì©Ê¥Ö½§ª¢ªº¯gª¬¤Î¦¨¦]¡A¨Ãµo®i¥X±wªÌ¡B¨ä·ÓÅU®a¤H¡BÂå®v¤Î¨ä¥LÂåÅ@¤H­û¶¡¨}¦nªº¤¬°ÊÃö«Y¤Î¨}¦nªº·¾³q¡C
 ·í¤p«Ä¦³²§¦ì©Ê¥Ö½§ª¢®É¡A©Ò¦³ªº®a¤¤¦¨­û³£¥i¯à¨ü¼vÅT¡A¦]¦¹¦pªG±wªÌ®aÄݤ]¯à±o¨ìÃB¥~ªºÀ°§U¥h¹ï§Ü®À§é¤ÎµL¤O·P¡A±N·|¦³©ÒÀ°§U¡C±wªÌªº¤p«Ä¥i¯à·|«ÜÃøÄñ¡AµLªk¨Ä¨Äªº¤£¥h·k§ì¤Î¼¯À¿¥Ö½§¡CÅý¤p«Ä¤À¤ß¡A§ä¤@¨Ç¨ÆÅý¤â¤£­n¶¢¤U¨Ó¡A¹ï±±¨î²§¦ì©Ê¥Ö½§ª¢¦³¯q¡A¦ý»Ý­n®aªø¤Î·ÓÅUªÌ¥Î¤ß¡C¥t¤@­Ó®aÄÝ­n­±¹ïªº¡A¬O¦]²§¦ì©Ê¥Ö½§ª¢¯gª¬¦Ó¤ÞµoªºªÀ·|¤Î±¡ºü®À§é¡C¤p«Ä¥i¯à¦]¦¹­±Á{¦b¾Ç®Õ¤¤©ÎªÀ¥æ¤W»Ùê¡A»Ý­n®a¤H´£¨ÑÃB¥~¨ó§U¤Î¹ªÀy¡C
 ¦¨¤H²§¦ì©Ê¥Ö½§ª¢±wªÌ¡A«h¥iÂǵ½¥[·ÓÅU¥Ö½§¡A¾Ç²ß¦p¦óªvÀø¦Ó§ïµ½¥Í¬¡«~½è¡C¦¨¤HÀ³¸Óµo®i¥X¤@®M¤é±`ªº¥Ö½§Å@²z¤è¦¡¡A¥B¨Ì¾ÚÀô¹Ò¤Î¥Ö½§ª¬ªp¥[¥H½Õ¾ã¡C½Õ¾ãÀ£¤O¡B¾Ç²ß©ñÃP§Þ¥©¥i¥H¨¾¤î¯e¯f´_µo¡C«Ø¥ß®a¤H¡BªB¤Í¡BÂåÅ@¤H­û¤Î¬ÛÃö¯f¤Í·|ªº³sô·|«Ü¦³À°§U¡CºC©ÊµJ¼{¤Îªq³à¥i¥HÂǥѵu´Áºë¯«ªvÀø¦ÓµÎ½w¡C
 §ä¥X³Ì·|§ìÄoªº±¡ªp¤]·|¦³À°§U¡A¨Ò¦p³\¦h±wªÌµo²{¶¢¤U¨Ó®É³Ì·|·k§ì¡A¦]¦¹°µ¤@¨Ç¨ÆÅý¤â¶¢¤£¤U¨Ó´N·|¦³®Ä¡C¿Ô¸ß¹ï±wªÌ¥Í²P³W¹º¤]«Ü­«­n¡A¨Ò¦p¦³¨Ç¤u§@·|®É±`±µÄ²¨ë¿Eª«½è©Î»Ý­n®É±`¬~¤â¡A¦p¼p®v¡B§Þ¤u¡BÅ@¤h¡B¬ü®e®v¡B¥~¬ìÂå®v¡B¤úÂå´N¤£¦X¾A²§¦ì©Ê¥Ö½§ª¢±wªÌ¡C
 
²§¦ì©Ê¥Ö½§ª¢ªº¬ã¨s²{ªp
(1) °ò¦]¡GÁöµM²§¦ì©Ê¥Ö½§ª¢¨ã¦³©úÅã®a±Ú¥v¡A¦ý°ò¦](¿ò¶Ç)©Ò§êºtªº¨¤¦â¤´¤£©ú½T¡C¦ü¥G²§¦ì©Ê¥Ö½§ª¢»P¤£¥u¤@­Ó°ò¦]¦³Ãö¡A¦b®a¤H¤¤¡A¥u­n¦³¤H¦³²§¦ì©Ê¯e¯f¡A¦pªá¯»¼ö¡B®ð³Ý¡A¨º»ò¤p«Ä¦³²§¦ì©Ê¥Ö½§ª¢ªº¾÷·|´N·|ª@°ª¡C¦pªG¤÷¥ÀÂù¤è³£¦³²§¦ì©Ê¯e¯f®É¡A¤p«Ä±o¯f¾÷·|¯S§O°ª¡A¦¹¥~¦b¦P§ZÂù­M­L¬ã¨s¤¤¡A80-90%ªº±¡ªp¤U¡AÂù¤è³£¦P®É·|¦³²§¦ì©Ê¥Ö½§ª¢¡A¦ý¦b²§§ZÂù­M­L®É¡Aµo¥Í¾÷·|¸û§C¡A¥u»P¤@¯ë¤H¬Û¦P¡C³o¨ÇÆ[¹î¡Aªí¥Ü°ò¦]ªº½T§êºt­«­n¨¤¦â¡C¦b¯S©w°ò¦]¬ã¨s¤è­±¡A²Ä¤G«¬T²Ó­M¿E¯À¬ÛÃöªº5q31-33¦ì¸m¡A¤Î°®Å~°ò¦]1q21¡B3q21¡B17q25¡B20p¡A³£µo²{¦³Ãö¡A¨ä¥L¦pSTAT-66¡BRANTES¡BIL-4¡BIL-4Ralpha¡BTGF-beta³£¦³¬ÛÃö¬ã¨s¡C
(2)¥Í¤ÆÅܤơG¾ÇªÌ»{¬°¥Ö½§«OÅ@¥\¯àªº§ïÅÜ¡A¨Ï±o²§¦ì©Ê¥Ö½§ª¢±wªÌ¹ï¥~¨Ó¨ë¿Eª«¸û¬°±Ó·P¡C³o¨Ç¤H¥Ö½§ªº¯×ªÕ»Ä§t¶q¸û§C¡A«O·Ã¤Î¼u¤O¤U­°¡A¤Þ°_¥Ö½§°®Àê¥B±±¨îµoª¢ªº¯à¤O¤U­°¡C¨ä¥L¬ã¨s«h«ü¦V¤@ºØºÙ¬°³æ®Ö²yªº¥Õ¦å²yªº²§±`¡C²§¦ì©Ê¥Ö½§ª¢±wªÌªº³æ®Ö²y»s³y¤@ºØºÙ¬°¤þºØ¤zÂZ¯À(IFN-gamma)ªº§K¬Ìª«½è¤£¨¬¡A³y¦¨¹L±Ó²{¶H¡C¦¹ºØ¯Ê³´¤Þµo²§¦ì©Ê¥Ö½§ª¢±wªÌ¦å¤¤¤Î¥Ö½§ªº§K¬Ì¤Îµoª¢¤ÏÀ³¼W±j¡C
(3)E§K¬Ì²y³J¥Õ(IgE)¥¢½Õ¡GIgE¬O¤@ºØ±±¨î¹L±Ó¤ÏÀ³ªº§ÜÅé¡A§ÜÅé¬O§K¬Ì¨t²Î²£¥Í¡A¥Î¨Ó¿ëÃѤιï§Ü¡B®ø·À¯f¬r¡A²Óµß¤Î¨ä¥L«I¤Jªº¥~¨Óª«½è©Ò²£¥Íªº¯S®í³J¥Õ½è¡A¥¿±`±¡ªp¤U¡A¥u¦s¦b·¥¤Ö¶qªºIgE¡A¦ý80-90%ªº²§¦ì©Ê¥Ö½§ª¢±wªÌ¦å¤¤IgE·|ª@°ª¡C¦b¹L±Ó©Ê¯e¯f¡AIgE§ÜÅé¬O¹ïÀ³¤£¦P§Ü­ì¦Ó²£¥Í¡A·í³o¨Ç§Ü­ì»P¯S®í§K¬Ì²Ó­M¤WªºIgE¬Û¹J¡A§K¬Ì²Ó­M´N·|©ñ¥X¤£¦P¤Æ¾Çª«½è¡A¥]¬A²Õ´Ói¡C³o¨Ç¤Æ¾Çª«½è«h¤Þ°_­ý³Ý¡B¥´¼QÀ¡¡B¬y²\¡B¥Ö½§Äoµ¥¹L±Ó¯gª¬¡A¤£¹L²Õ´Óiµ¥¤Æ¾Çª«½è¨ÃµLªk§¹¥þ¸ÑÄÀ³o¨Çªø´Á¹L±Ó¯gª¬¡C¥Ø«e¹ï©óIgE¬°¦ó¹L¶q²£¥Í¡A¨ä­P¯f¾÷ Âର¦óªº¬ã¨s¥¿¦b¶i¦æ¤¤¡CIgE¬O¨ä¥¦¹L±Ó©Ê'¨ä¯e¯f­«­n«ü¼Ð¡A¦ý¦b²§¦ì©Ê¥Ö½§ª¢¤W¡A«h¦³ª§Ä³¡C¼Ú¬w¹L±Ó¤ÎÁ{§É§K¬Ì¾Ç·|«Øij±N²§¦ì©ÊÀã¯l¤À¬°IgE¶§©Ê¤Î³±©Ê¨âÃþ¡A¦Ó2004¦~¥@¬É¹L±Ó²Õ´(world allergy organization)¬Æ¦Ü«Øij¥u¦³IgE¤É°ª®É¤~ºÙ¬°²§¦ì©Ê¥Ö½§ª¢¡A¦ý¨Ã¥¼¨ü¨ì¥þ­±±µ¨ü¡C
(4)§K¬Ì¨t²Î¥¢¿Å¡G¬ã¨s¤H­û»{¬°§K¬Ì¨t²Î¥¢¿Å»P²§¦ì©Ê¥Ö½§ª¢§Î¦¨¦³Ãö¡A¦ü¥G§K¬Ì¨t²Î¤¤¡A­t³dIgE»s³yªº³¡¤À¹L«×¬¡ÅD¡A¦Ó­t³d³B²z¥Ö½§¯f¬r¡AÅðµß·P¬Vªºªº³¡¤À«h§Î¦¨¤£¨}¡A³o¨Ï±o²§¦ì©Ê¥Ö½§ª¢±wªÌ®e©ö¥Ö½§·P¬V¡C³o¼Ëªº§K¬Ì¥¢¿Å¨Ï±o¥Ö½§µLªk±±¨îµoª¢¤ÏÀ³¡A¬Æ¦Ü¦b¥~Æ[¥¿±`ªº¥Ö½§¤W¡A¤]¤Þ°_µoª¢¤ÏÀ³¡C¦b¤@¨Ç¬ã¨s¤¤¡Aª÷¶À¦â¸²µå²yµßªº¨¤¦â¯S§O³Q¬ã¨s¡C
¬ã¨s¤H­û¬Û«H¡A¥Ö½§¤@ºØºÙ¬°Äõ®æ¨u¤ó²Ó­Mªº§K¬Ì²Ó­M¡A»P²§¦ì©Ê¥Ö½§ª¢¦³Ãö¡C¦¹²Ó­M·|§ä¥X¤J«I²Ó­Mªº¯f¬r¡B²Óµß¡B¹L±Ó­ì¤Î¨ä¥Lª«½è¡A±N³o¨Çª«½è¶Ç°eµ¹§K¬Ì¨¾Å@¨t²Î¤¤ªº¨ä¥L²Ó­M¡AÄõ®æ¨u¤ó²Ó­M¦b²§¦ì©Ê¥Ö½§ª¢±wªÌªº¥Ö½§¤¤¦ü¥G¹L«×¬¡ÅD¡A¬¡¤Æ¤F¥Õ¦å²y¤¤ªºT²O¤Ú²Ó­M¡AT²Ó­M¤S¦A²£¥Í«P¨Ï¹L±Óªº³J¥Õ½è¡A³o¼Ëªº¥\¯à¨Ï±o¥Ö½§¹ï¤Ö¶qªº¹L±Ó­ì²£¥Í¹L«×ªº¤ÏÀ³¡C
¥Ø«e¾ÇªÌ¥¿§Q¥Î¦Ñ¹«ªº¹êÅç¼Ò¦¡¡A³v¨B¬ã¨s²§¦ì©Ê¥Ö½§ª¢ªº§K¬Ì¨t²Î¡A´Á«Ý¯à§ä¥X¦³®Äªº§K¬ÌÀøªk¡C
 
(5)ÃĪ«¬ã¨s¡G
 ¥Ø«e¾ÇªÌ¥¿°w¹ï²§¦ì©Ê¥Ö½§ª¢ªº·sÀøªk¥[¥H¬ã¨s¡A¨ä¤¤¥]¬A¥Íª«»s¾¯¡B¸É¥R¯×ªÕ»Ä¡B¤Î·sªº·Ó¥úÀøªk¡A¨Ò¦pµµ¥~½u¦p¦ó¼vÅT¥¿±`¤Î¦³¯f¥Ö½§ªº§K¬Ì¨t²Î¡C¥t¥~¤]¦b¬ã¨s¤¤ªº¥]¬A¤@¨Ç¥Íª«»s¾¯¡A¦pmepolizumab(IL-15§ÜÅé)¤Îomalizumab (Zolaire)¡A©Ò¿×¥Íª«»s¾¯¬O«ü¤@Ãþ®Ú¾Ú¨­Å饿±`¦s¦bª«½è¡A¦Ó¬ãµo¥Xªº·s«¬ÃĪ«¡A¨ä¤¤ ¥Î¯Ý¸¢¯Àthymopentin¦ü¥G¬O¨ã¦³µo®i¼ç¤OªºÃÄ«~¡A¯à°÷­««Ø§K¬Ì¨t²Î¥­¿Å¡C¦ÓOmalizumab¤@¯ë¦Ó¨¥¨ÃµL¤Ó¬ð¥XªºÀø®Ä¡A³»¦h¥i¹Á¸Õ¥Î©ó¥~¦]©Ê²§¦ì©Ê¥Ö½§ª¢¥BIgE§e¤¤«×¤W¤ÉªÌ¡C ¸û·s³ø¾É¬OIL-4 receptorªº³æ®è§ÜÅé dupilumab ¡A¤£½×¾¯¶q(75, 150, or 300 mg)¦b¨Ï¥Î4©P«á80% ±wªÌ§ïµ½¦Ü¤Ö25% (EASI-25)¡A¦w¼¢¾¯²Õ«h¬°25%, ·íµM¾¯¶q°ª®ÄªG¦n¡A150 ¤Î 300 mg¤À§O¬° 50% ¤Î 75% 
 ¥t¤@¤è­±¡A¬ã¨s¤H­û¤]¦bÄ~Äò´M§ä§K¬Ì§í¨î¾¯¡A¦b³o¤è­±¡A°£¤F­ì¥ýªºÀôÌUÅð¯À(cyclosporin)¥~¥Îtacrolimus¤Îpimecrolimus¥~¡A¤fªAªºpimecrolimus¤]¦bµo®i·í¤¤¡A³Ì²×¥Øªº¬O­n¯à¨ú¥NÃþ©T¾Jªº¨Ï¥Î¡C¨ä¥L¦p apremilast, Crisaborole (¥~¥Î PDE-4§í¨î¾¯), dupilumab, IL-37, rituximab, , infliximab, allergen-specific immunotherapy, Mycobacterium vaccae, leflunomide, REGN668(interleukins 4 and 13³æ®è§ÜÅé)
 ÁÙ¦³¤@¨Ç¹êÅç©ÊªºÀøªk¡A¬O¦b¹Á¸Õ¸É¥R²§¦ì©Ê¥Ö½§ª¢±wªÌ©Ò¯Ê¥Fªºª«½è¡C²§¦ì©Ê¥Ö½§ª¢±wªÌªº¥Ö½§¯Ê¥F¤þºØ¦¸¨È³Â¤¯ªo»Ä¡A¦Ó¤ë¨£¯ó¤¤«h´I§t¦¹ºØ¯×ªÕ»Ä¡C¥Ø«e¹ï¸É¥R¤ë¨£¯óªoªºÀø®Ä¥¿¡B¤Ï³£¦³¡A¦Ó¶¼­¹¤¤²K¥[¦¹¯×ªÕ»Ä¤]¥¼¨£©úÅã®ÄªG¡A¥t¥~¨Ï¥Î¤¤¯óÃÄ©ÎÃįó¯ù¨ÓªvÀø¤]¤Þ°_²³¦h¿³½ì¡C²{¦³¸ê®ÆÅã¥Üªº½T¦³¨ÇÀø®Ä¡A¦ý³o¨ÇÃį󪺥i¯à¬r©Ê¡A¤Î¦Û¦æ¥¼¸gÂåÀøºÊ·þ¤U¨Ï¥Î³o¨Ç¨ã§í¨î§K¬Ì¥\¯àÃį󪺭·ÀI¡A¤´À³¤p¤ß¡C¶Ê¯vÀøªk¤Î°w¨b(Allergy, 65/7, 2010 , 903-91)¦b¥¿¦¡´ú¸Õ¤¤¤]³Qµo²{¦³³¡¥÷Àø®Ä¡A¦ý¾÷Âର¦ó¤´«Ý¼á²M¡C¥Íª«¦@®¶¶EÂ_ (biological resonance diagnosis)¬O¤@ºØÅé¥~¶EÂ_¡A«ÅºÙ¥i¥HÀ°¦£§ä¨ì¤Þ°_¥Ö½§¤£¾Aª«½è¡A¦ý¦³®Ä²v¤£°ª(JCli Derm 2013;42:626)
 
µ²»y
®Ú¾Ú²{¦³ªº¬ã¨s¡A§Ú­Ì¹ï©ó²§¦ì©Ê¥Ö½§ª¢ªº³B²z´£¥X¥H¤U«Øij¡G
(1) ¨¬°÷ªº¸ÑÄÀ»P±Ð¨|
(2) ¤Ñ§N®É¿ï¾Ü¾A·íªº«OÀ㾯¨Ï¥Î
(3) ¨Ì¾Ú¦~ÄÖ¡B³¡¦ì¤Î±w¯f½d³ò¿ï¾ÜÃþ©T¾J
(4) ¥~¥ÎTIM(«DÃþ©T¾J§K¬Ì½Õ¸`¾¯)°£©óÁy³¡¡B©ÎÃþ©T¾J¦¨Å}ªÌ¥~¡A¤´À³¥Î©ó¤G½uªvÀø¡A¥BÀ³µu´Á¡A©Î¶¡Â_¨Ï¥Î
(5) ¥i¯à·|¦]¬°²Óµß©Î¯f¬r©Î±µÄ²©ÊÀã¯l¦Ó´c¤Æ
(6) ²M°£¹ÐÂڥثe¨Ã¤£«Øij¡A¦ýÀ³«O«ù«Ç¤ºªÅ®ð¬y³q¡A§Y¨Ï¦b¥V©u¡CÁקK¦a´à¡A¥HÀã®ü´Ö²M²z¦Ç¹Ð¡C¨C¶g¤@¦¸¥H§l¹Ð¾¹²M²z¡C©ó·nÄx¤º©Î§É¤Wª«©ñ¸m µLªk²M¬~ªºsoft toy¡C¨C10¤Ñ¥H°ª©ó55«×¼ö¤ô²M¬~§É³æ¡C¥i¥HGortex©Î¬Û¦ü§÷½è¥]»qÂл\§É³æ¤ÎªEÀY
(7) ¶¼­¹­­¨î¦b¦¨¤H»ù­È«Ü§C¡A§Y¨Ï¦b¤p«Ä¡A¤]À³¦bÂå®v±K¤Á¤U°õ¦æ
(8) ¤ë¨£¯óªoªºªvÀø»ù­È©|¥¼½T¥ß
(9) Ãh¥¥¤Î­÷¨Å´ÁªA¥Î¸z¯qµß¥i©µ½w²§¦ì©Ê¥Ö½§ª¢µo§@
(10) ²§¦ì©Ê¶K½§¸ÕÅç¥i¥Î©ó¶EÂ_ªÅ®ð¶Ç¼½©Ê¹L±Ó
(11) §t»È¦çª«¥i§ïµ½¥Ö½§¯gª¬¡A¦ýªø´Á¦w¥þ©Ê¤´»ÝÆ[¹î

(12)¸z¯qµß¹ï¤p¨à¸¡Âm¨ã¤@©wÀø®Ä¡A¦ý¦bªvÀø²§¦ì©ÊÀã¯l¤WÀø®Ä¦sºÃ¡C¦Ü©ó¦b¹w¨¾¤W¥i¯à¦³®Ä¡A¦ý»Ý°ª¶q(¤@¯ë¨Ï¥Î½¦Ån)­¹¥Î¦X¾AµßºØ¡A§Y¨Ï¦PÄݦPºØ²Óµß¡A¤£¦P«~ºØ¤]¥i¯à®ÄªG¤£¦P¡C

(13)¦çªAÀ³¸ÓÁקK¨ë¿E©ÊÅÖºû§÷½è¡A¦p¦Ï¤ò¡B²ÊÅÖºû¡AÁקK¬ïµÛ¹L¶È¹L·x¡A¥H¨¾¤î¥X¦½¨ë¿E

(14)ÁקK©âµÒ¤Î±µÄ²­»µÒ

(15)ª×«Ç«O«ù²D²n¡AÁקK¹L¦h§É¹Ô

(16)ÁקK·P¬V疱¯l¡A¦p¤w¦³·P¬VªÌ¡A¦³疱¯lµo§@®É¡A¯S§O¬O¦³²§±`ªí²{®ÉÀ³¾¨§Ö´NÂå

(17)¥¿±`¬Ì­]±µºØ©ó¥¿±`¥Ö½§³B

(18)¤£»Ý¨è·N­­¨î¤éÅΡA¦]¤éÅΤ@¯ë¥i¥H§ïµ½Àã¯l¦Ó¨Ï¥Ö½§»Ù¾À¥\¯à´£¤É

(19)¥i¥H¹B°Ê¡A¦p¬y¦½¤Þµo´c¤Æ®É¡A¥iºCºC¼W¥[¹B°Ê±j«×²£¥Í¾AÀ³¡C´åªa«á²O¯D¨Ã¨Ï¥Î«OÀã²£«~

(20)¥i¯àªº¸Ü­÷¨Å¨ì4­Ó¤ë¡Cµ¹¤©¥¿±`¶¼­¹¤º®e¡A°£«DÀˬd«á½T©w»Ý­n±Æ°£¯S©w­¹ª«¡C¤£¹L¤¦³Á¤]¦³¬ã¨sÅã¥Ü¥À¿Ë¦p¦³®ð³Ý¡A­÷¨Å¶V¤[¡A¤p«Ä¤Ï¦Ó®e©öÀã¯l¡A¤£¹L­ý³Ý­Ë¬O´î¤Ö¡C(J Allergy Clin Immunol 2010)

(21)ÁקK¹}¾i¤òµ³µ³ªºÃdª«¡A­Y½T©w¹L±Ó®É¡A­nÄY®æ°õ¦æ

(22)ªá¯»©u¸`¡A·í®ð­Ô·Å·x°®Àê®É­nÃö¤Wªùµ¡¨Ã¾¨¥i¯à¯d¦b«Ç¤º¡C±ß¤W¡B²M±á¤Î«B¤Ñ®É«h«O«ùªÅ®ð¬y³q¡C¤£­n¥h°ª¦MÀIÀô¹Ò¡A¦p¾S¯ó®É¡C¥i©ó¨®¤¤¥[¸Ëªá¯»¹LÂo¾¹¡C

 

 

ÁöµM²§¦ì©Ê¥Ö½§ª¢·|¤Þ°_¤£¾A¤Î¤£«K¡A¦ý²§¦ì©Ê¥Ö½§ª¢¬O¥i¥H¦³®Ä±±¨îªº¡A²§¦ì©Ê¥Ö½§ª¢±wªÌ¬O¥i¥H¦³°·±d¡B¥¿±`ªº¥Í¬¡¡C·í¬ã¨s¤H­û³v¨B¤F¸Ñ²§¦ì©Ê¥Ö½§ª¢¤Î¨ä¦¨¦]¡A¤]´N´Â¦V§ó¦³®ÄªvÀøÁÚ¶i¤@¨B¡A³Ì²×©Î³\¯u¦³ªv¡²§¦ì©Ê¥Ö½§ª¢ªº¤@¤Ñ¡C

 

(Àø®Ä¤ñ¸ûClin Cos Invest Dermatol 2010:3:99)

 

¾¯¶q

ªvÀø´Á

®ÄªG(¤H¼Æ)

°Æ§@¥Î

¶O¥Î

MTX

15mg/©P

24©P

ÄY­««×¡õ52%(12)

10%°±ÃÄ

 °·«O

MTX

7.5~25mg/©P

3¤ë

75%¦³®Ä(20)

 

 °·«O

 

Imuran

2.5~3.5mg/kg

12©P

37%ÅãµÛ(42)

11%°±ÃÄ

 °·«O 

Imuran

2.5~3.5mg/kg

5¤ë

40.5%²¬Â¡(37)

5/37°±ÃÄ

 

 °·«O

CsA

5mg/kg

>6¤ë

77% (73)

8%°±ÃĤϼu

 ¦Û¶O

CsA

3~5mg/kg

6~8©P

55% (602)

10~15%µÇ¬r©Ê

 ¦Û¶O 

Rituximab

1gm qow X 2

4~8©P

100% (6)

µL

  ¦Û¶O

Cellcept

2~4 mg/¤Ñ

12©P

ÄY­««×¡õ68%(20)

5/20 HZV, HSV; 2/20ª÷¶À¦â¸²µå²yµß·P¬V

 

 ¦Û¶O

(ªí¥~¦b´c¤Æ¦]¤l)

¦]¯À

¬ÛÃö©Ê

¨Ò¤l

ªÀ¸g¦a¦ì

¤¤«×

½Ã¥Í²z½×¡A«°¥«¤Î¶m§ø

Áý¥À¨Å

¤´¦³ª§Ä³

²£«á«e3¤ë¥uÁý¥À¨Å

¥~¦b¨ë¿Eª«

±j

°®Àê¡B²M¼ä¾¯¡B¤ô¡B·»¾¯¡B±þµß

±µÄ²¹L±Ó­ì

±j

Âì¡B­»ºë¡B¨¾»G¾¯

¥~¦bÄa¯BªÅ®ð¹L±Ó­ì

¤¤«×

¶K½§¸ÕÅç

§l¤J©Ê¹L±Ó­ì

±j

¹Ð螨¡BÃ~¤ò¡Bªá¯»¡BÅðµß

Àô¹Ò¦Ã¬V

®z

¨T¨®±Æ©ñ

­¹ª«

¤p¨à¸û¬ÛÃö

³J¡B¥¤¡B³Á¡B¶À¨§¡Bªá¥Í

®ð­Ô

±j

Àã«×¡F®ðÀ£¡B¤éÅθû¤£­«­n

·L¥Íª«

­«­n

ª÷¶À¦â¸²µåµß

Åðµß

°£¥Ö®hªÞÌUµß¥~¨ä¥L¤´¦³ª§Ä³

¥Ö®hªÞÌUµß¡A©À¯]µß¡H¥ÖÅ~µß¡H

¯f¬r

®z

©ö¦³疱¯l¡A¨ä¾lµLÃö

À£¤O

¤¤«×

50%¦³Ãö

ªí¥Ö»Ù¾À¯Ê·l

±j

°ò¦]¤Î¥~¦]¦@¦P§@¥Î

°ê¤º¬ÛÃöº}¥Õ¤ô¥~¥Î²£«~

1 Smile ¨p±K¼Ö (chloridohydridooxygen 0.015% + sodium hypochlorite 0.005%)

2. SupercleanµÎ§J²M(chloridohydridooxygen 0.015% + sodium hypochlorite 0.005%)

3.Natural Water¤ô¦ÛµM«äÌW¼ä²b¼QÃú¡B²`¼h¹à¥Õ²b½§¤ô(Zynk Industry)(100~200 ppm)

4. NeuKocyte¥ß¥i¾AÀH¨­§Üµß¼ä½§¾®ÅS¡B¼ä½§Å@¤â¾®ÅS¡B¼ä²b§Üµß¼Q¾¯¡B¼ä²b½§¤ô (30ppm)

5. Microdacyn60ÁÚ¥iªY¶Ë¤f²M¼ä§Üµß²G (40-85ppm)½Ã³¡Âå¾¹¿é¦r²Ä027118 ¸¹



»OÆWMASTÀË´ú¶µ¥Ø36¶µ

±i¶K¤é´Á¡G2004/7/28